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Abstract 
Individuals with type 2 diabetes (T2D) are prescribed aerobic exercise as treatment, 
however, peripheral arterial disease (PAD), a complication of T2D, restricts lower 
extremity blood flow causing claudication during the activity. Isometric exercise has 
been shown to increase local blood flow in other populations. This thesis tested the 
hypothesis that bilateral lower extremity isometric training would increase both initial 
(ICD) and absolute claudication distances (ACD) by increasing blood flow. Four males 
with T2D and PAD performed 4, 2-minute bilateral lower extremity isometric 
contractions at 30% of their maximal effort, 3X/week for 6-8 weeks. Pre and post-
exercise ICD, ACD and blood flow were measured before and after the intervention. 
ICD and ACD increased 116.3+26.3% and 47.5±34.1%, respectively (Z=2.475; p=.008) 
with bilateral lower extremity isometric training, however, pre and post-exercise blood 
flow remained unchanged. These findings suggest that bilateral lower extremity isometric 
training increases ICD and ACD by a mechanism other than increased blood flow. 
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CHAPTER 1: Introduction and Literature Review 
l 
1.1 Diabetes Mellitus (DM) 
1.1.1 Introduction 
Diabetes mellitus (DM) is a disease characterized by elevated blood glucose 
(hyperglycemia) due to inadequate insulin secretion or action (Centers for Disease 
Control and Prevention, 2010). It affects over 180 million people worldwide, a figure 
that will likely double by 2030 (World Health Organization, 2008). DM is a prominent 
risk factor for the world's leading cause of death, cardiovascular disease, and over half of 
the individuals diagnosed with diabetes die before the age of 70 (World Health 
Organization, 2009a; Grundy et al., 1999). The only non-infectious disease classified as 
an epidemic, DM is not the result of genetic factors alone, as both the environment and/or 
an individual's behaviour (such as a sedentary lifestyle and high calorie diet) often play a 
major role in its development (World Health Organization, 2008; Zimmet, Alberti, & 
Shaw, 2001). 
Before discussing, in detail, the different types of DM, it is important to first 
understand blood glucose and its regulation in a healthy population. 
1.1.2 Blood Glucose Regulation 
Blood Glucose 
Glucose, a monosaccharide or simple sugar, is a type of carbohydrate (molecules 
composed of atoms of carbon, hydrogen and oxygen), a fuel that can rapidly provide the 
body with energy (National Diabetes Information Clearinghouse, 2008). Blood glucose 
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refers to the amount of glucose present in blood (Candian Diabetes Association, 2008). 
The normal fasting blood glucose level in humans is 4.0 mM-6.0 mM (Canadian Diabetes 
Association, 2008). With the ingestion of food or drink composed of this simple sugar, 
the blood glucose level will rise and alter the body's internal environment (National 
Diabetes Information Clearinghouse, 2008). 
Negative Feedback and Blood Glucose Regulation Mechanisms 
One of the goals of the human body is to maintain a constant internal environment 
or homeostasis. The regulation of blood glucose is accomplished through a negative 
feedback system. In general terms, this negative feedback system is composed of three 
elements: a sensor, a control center and effectors. A change in the internal environment 
acts as a stimulus that is detected by the sensor. The sensor sends a signal to the control 
center which assesses the amount of change that has occurred in the internal environment, 
then the control center sends the appropriate signal to the effectors. The effectors 
produce a response to correct the change in the internal environment that was detected. 
This feedback system is considered a negative feedback system because the response it 
produces is negative or opposite of the stimulus. (Powers & Howley, 2009) 
In relation to blood glucose regulation, a blood glucose concentration that is 
elevated above normal (a change in the internal environment) is the stimulus detected by 
the sensor (the pancreas) and the signal sent to the effector (also the pancreas) from the 
control center is to increase insulin secretion (insulin is responsible for increased glucose 
uptake by cells) which, in turn, decreases the blood glucose concentration (see Figure 1) 
(Aserita, 1985). 
3 
Blood glucose regulation mechanisms are responsible for the success of this 
negative feedback system. After the digestion of a meal or drink containing 
carbohydrates blood glucose levels can increase to levels as high as 8 mM (Jewell, Oh, & 
Thurmond, 2010; Canadian Diabetes Association, 2008). The glucose molecules (which 
have increased in number) travel through the bloodstream to pancreatic beta-cells (Jewell, 
Oh, & Thurmond, 2010). These molecules then attach to the membrane spanning glucose 
transporter proteins (GLUT2) of the beta-cell and enter via facilitated diffusion (Inagaki 
et al., 1992). While in the beta-cell, glucose is acted on by the enzyme glucokinase to 
produce glucose-6-phosphate and it undergoes the processes of glycolysis (see Figure 2), 
the Kreb's cycle (see Figure 3) and the electron transport chain (see Figure 4) to produce 
molecules of the energy compound adenosine triphosphate (ATP) (Inagaki et al., 1992). 
The resultant increase in ATP is responsible for closing the ATP-sensitive 
potassium channels located on the beta-cell membrane and this leads to the depolarization 
(membrane potential is dependent on potassium flux) of the membrane, thus opening the 
voltage-gated calcium channels and allowing calcium to enter the cell (Atwater, Dawson, 
Eddlestone, & Rojas, 1981). This increase in calcium in the cell induces the release of 
more calcium from the intracellular endoplasmic reticulum by activating phospholipase C 
which cleaves phosphotidylinositol-4,5-biphosphate (PJP2) into inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (IP3 binds to a receptor protein in the endoplasmic 
reticulum initiating calcium release) (Atwater et al., 1981). The further increase in 
calcium causes the release of insulin from the beta-cell by influencing exocytosis (see 
Figure 5) (Jewell, Oh, & Thurmond, 2010). 
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The newly released insulin binds to insulin receptors on skeletal and cardiac 
muscle cells and this action causes the activation of the enzyme tyrosine kinase which 
phosphorylates (activates through the donation of a phosphate ion from adenosine 
triphosphate breakdown) insulin receptor substrate proteins (Robinson & Buse 2008). 
The activated insulin receptor substrate proteins then bind to and subsequently activate 
phosphotidylinositol-3 kinase which in turn activates protein kinase B (Robinson & Buse, 
2008). Protein kinase B phosphorylates the protein AS 160 (which is responsible for 
converting the Rab protein into its inactive form of guanosine diphosphate) and 
dissociates it from the glucose transporter protein located inside the muscle cell (GLUT4) 
(Hardie, 2002). Once dissociated, AS 160 no longer promotes the Rab-guanosine 
diphosphate conversion and the Rab gets converted into its active form, guanosine 
triphosphate which causes the translocation of GLUT4 to the cell membrane (Klip & 
Paquet, 1999; Hardie, 2002). It should be noted that at all times there are GLUT4s 
located on the cell membrane, but the aforementioned process increases the number of 
GLUT4s located on the cell membrane (Klip & Paquet, 1999). Extracellular glucose 
molecules enter the cell by binding to the membrane spanning GLUT4s (see Figure 6) 
(Klip & Paquet, 1999). Once inside the muscle cell, the glucose can be broken down 
during glycolysis (see Figure 2), the Kreb's cycle (see Figure 3) and the electron 
transport chain (see Figure 4) to produce energy compounds (such as ATP) or it can be 
converted into stored energy in the form of glycogen through glycogenesis (see Figure 7). 
As glucose progressively enters the muscle cells, blood glucose levels fall 
concurrently, with an eventual return to within a normal range (Jewell, Oh, & Thurmond, 
2010). This is the end result of the negative feedback system under normal conditions 
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(Powers & Howley, 2009). In a pathology such as DM, some of the mechanisms do not 
work properly and blood glucose levels do not return to normal unless a form of therapy 
is administered (Canadian Diabetes Association, 2008). 
1.1.3 DM- A Closer Look: Types, Pathophysiology and Risk Factors 
The DM population can be divided into three groups: Those with type 1 diabetes 
(T1D; the body lacks insulin), those with type 2 diabetes (T2D; the body is resistant to 
insulin) and those with gestational diabetes (GD; affects women during pregnancy) (see 
Table 1) (Berg, 1986). 
Type 1 DM (T1D) 
Pathophysiology of T1D 
Although the causes of type 1 DM (T1D) have long been purported to be genetic 
and/or environmental another prominent theory in the diabetes literature is that 
individuals are insulin-dependent because the beta-cells of the pancreas that produce 
insulin are destroyed by the body in an autoimmune attack (Cihakova, 2001). 
The trigger and the process for this autoimmune attack are still unknown 
(Cihakova, 2001). One theory involves cytotoxic T-cells. Cytotoxic T-cells are 
lymphocytes (white blood cells) that destroy viruses, infected cells and cells labeled by 
programmed cell death (these cells usually have a bulging or unattached cell membrane) 
(Ueda et al., 2003). The cytotoxic T-cells infiltrate the islets of Langerhans (the area 
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within the pancreas where the beta-cells are situated) and begin destroying beta-cells 
(Ueda et al., 2003). 
Whatever the cause, the destruction of beta-cells means that insulin cannot be 
produced or secreted by the body. Thus, the negative feedback system fails and 
hyperglycemia results (American Heart Association, 2011). As in healthy individuals, 
after ingestion of carbohydrates, blood glucose increases in a person with TID (Canadian 
Diabetes Association, 2008). Glucose molecules travel through the blood stream and in 
healthy individuals, some glucose molecules travel to the pancreatic beta-cells to 
stimulate insulin secretion. In contrast, with TID, there are no beta-cells to travel to and 
thus no insulin to release (Kloppel, Lhor, Habich, Oberholzer, & Heitz, 1985). Insulin is 
responsible for increasing the number of GLUT4s (glucose transporter proteins) on the 
muscle cell membrane (Klip & Paquet 1999). Without insulin, the number of GLUT4s 
during this state of increased blood glucose concentration remains the same as during the 
state of fasting blood glucose concentration (Klip & Paquet, 1999). There are too many 
glucose molecules for the GLUT4s to transport into the muscle cell and hyperglycemia 
results. The destruction of the beta-cells can progress for many years before it is detected 
and this is because symptoms (such as hyperglycemia and ketoacidosis) only develop 
when 90% of the cells have been destroyed (Cihakova, 2001). 
Risk factors for TID 
Individuals with TID may have a genetic predisposition to contracting the 
disease. If a female under the age of 25 years with TID gives birth, her child has a 1 in 
25 chance of developing TID, but the risk decreases as the age of the birthing mother 
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increases (Permutt, Wasson, & Cox 2005). If a man has T1D, then the chances of his 
child developing the disease are 1 in 17, but if both parents have T1D then the risk can 
increase to 1 in 4 (Permutt et al., 2005). In addition, there are some environmental 
factors associated with T1D disease development. It has been noted that T1D develops 
more frequently in children who live in places with cold climates and in children who 
were exposed to a viral infection (American Diabetes Association, 2009). Also, children 
who were not breastfed and began eating solid foods at an earlier age had a greater 
chance of developing T1D (Permutt et al., 2005). Even though individuals may differ in 
the method of contracting T1D, they all share the commonality of destroyed or decreased 
pancreatic beta-cells (Kloppel et al.,1985). 
Type 2 DM (T2D) 
Type 2 DM (T2D) is also known as adult-onset, insulin-resistant or noninsulin-
dependent diabetes, and accounts for 90-95% of all the documented DM cases 
(University of Virginia Health System, 2007; Berg, 1986). T2D is considered adult-onset 
because the disease usually affects individuals after the age of 40 years, although there 
has been a recent significant increase in the number of children under the age of 16 years 
who develop the disease (Berg, 1986; American Diabetes Association 2009). Individuals 
are non-insulin dependent because although the body has the beta-cells to produce 
insulin, the muscle cells are resistant to it (Weyer, Bogardus, Mott, & Pratley, 1999). 
Hyperglycemia results from the delayed glucose uptake by muscle cells on account of the 
insulin resistance, and the negative feedback system fails (Weyer et al., 1999). T2D 
occurrence depends on genetic predisposition and environmental influence (Canadian 
Diabetes Association, 2011). 
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Pathophysiology of T2D 
There are four stages in the development of T2D (Weir & Bonner-Weir, 2004). 
These stages are insulin resistance, altered beta-cell function, continuous increase of 
fasting blood glucose concentration and disease (Weir & Bonner-Weir, 2004). In the first 
stage, the beta-cells produce insulin in response to increased blood glucose levels, but the 
muscle cells have a reduced ability to take up glucose at that particular blood insulin 
concentration (Weir & Bonner-Weir, 2004). The muscle cells' insulin receptors do not 
allow any insulin to bind and the GLUT4s are not translocated to the cell membrane to 
increase the transport of glucose into the cell (Klip & Paquet, 1999). The beta-cells, in 
turn, produce more insulin in an attempt to increase insulin-insulin receptor binding and 
promote increased glucose uptake (Weir & Bonner-Weir, 2004). This increase in insulin 
production causes the beta-cells to increase in number and size (Weir & Bonner-Weir, 
2004). In some individuals, the beta-cells cannot produce the amount of insulin needed 
for adequate insulin-insulin receptor binding and adequate glucose uptake, and 
hyperglycemia results (Weir & Bonner-Weir, 2004). 
The phenomenon of insulin resistance and its causes are still not fully understood. 
It is unknown why the muscle cells become resistant to the insulin that is secreted to 
increase glucose uptake. There are, however, some common characteristics among 
individuals with insulin resistance such as abdominal obesity (a waist circumference of 
greater than 102 cm and 88 cm in men and women, respectively), dyslipidemia (an 
abnormal lipid profile of hypertriglyceridemia (increased triglyceride levels of >1.7 mM), 
high low-density lipoprotein (LDL) (>3.4 mM) and a low level of high-density 
lipoprotein (HDL) (<1.0 mM and <1.3 mM in men and women, respectively)), 
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hypertension (sustained elevations in resting arterial blood pressure; BP) and increased 
fasting blood glucose concentration. Although the causes of insulin resistance are 
unknown, a potential long term outcome is T2D. (Canadian Diabetes Association, 2008) 
The second stage of T2D development is altered beta-cell function. With insulin 
resistance and decreased glucose uptake, an individual's fasting blood glucose level 
increases from the normal ~4.0 mM to >5.6 mM (Brunzell et al., 1976). As fasting blood 
glucose levels approach 5.6 mM, beta-cells begin to secrete less insulin (Brunzell et al., 
1976). Combined with insulin resistance, this decrease in insulin secretion contributes to 
hyperglycemia because less insulin is available to help promote glucose uptake (Weir & 
Bonner-Weir, 2004). Eventually the fasting blood glucose levels are increased beyond 
6.7 mM, a level at which insulin secretion almost completely ceases (Brunzell et al., 
1976). The molecular mechanisms behind the loss of insulin secretion are unknown, but 
glucose toxicity offers a potential explanation (Brunzell et al., 1976). Beta-cells function 
in an optimal range of blood glucose concentration (4.0 mM-6.0 mM) and if the blood 
glucose levels increase too high (>6.7 mM), the constant internal environment changes 
and the functions of the beta-cells begin to alter and almost cease (Brunzell et al., 1976). 
Altered beta-cell function and loss of insulin secretion lead to even less glucose uptake 
and a greater degree of hyperglycemia (Weir & Bonner-Weir, 2004). 
In the third stage of T2D development, the fasting blood glucose levels continue 
to rise above 7.4 mM due to the insulin resistance of muscle cells and the impaired 
insulin secretion of the pancreatic beta-cells. From stage three, it can take an individual 
several years before they reach stage four, fully developed T2D. In stage four, the body 
produces just enough insulin to allow muscle cells to take up some glucose and combat 
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ketoacidosis (decrease in arterial pH due to the presence of excessive ketones from fat 
metabolism in lieu glucose metabolism) (Weir & Bonner-Weir, 2004) 
Risk factors for T2D 
Environmental factors have a significant influence on T2D development 
(American Diabetes Association, 2004). Individuals who are obese or who lead the 
"Western" lifestyle (calorie-rich diet, high-fat diet and low physical activity) are at risk 
for T2D, especially if they have a family history of the disease (Malecki, 2005). If one 
parent has been diagnosed with T2D before the age of 50 years, then the child has a 1 in 7 
chance of developing T2D, but the risk does decrease as the parent's age of onset 
increases (Malecki, 2005). If both parents have been diagnosed with T2D at any age, 
then the child has a 1 in 2 chance of developing T2D (Malecki, 2005). 
Gestational Diabetes (GD) 
Gestational diabetes (GD) affects approximately 4% of all pregnant women, and 
represents new-onset hyperglycemia and T2D during pregnancy (Canadian Diabetes 
Association, 2009; Campbell et al., 2009). Women who are above the age of 35 and/or 
are obese have an increased risk of developing GD (Canadian Diabetes Association, 
2009). Also women who have had GD in the past or have given birth to overgrown 
babies increase their chances of developing the condition (Canadian Diabetes 
Association, 2009). If an affected woman does not control her GD, not only does she 
increase her risk of developing T2D later in life (Canadian Diabetes Association, 2009), 
she increases nutrient availability to her fetus which contributes to fetal overgrowth and 
adiposity (Catalano,Kirwan, Haugel-de Mouzon, & King, 2003). 
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Pathophysiology and risk factors for GD 
Much like T2D, the exact cause of GD is unknown, but insulin resistance (see 
Pathophysiology of type 2 diabetes) is an integral part of the condition (Catalano et al., 
2003). Another potential cause of GD is abnormal beta-cell sensing of glucose (Catalano 
et al., 2003). On the pancreatic beta-cell, the glucose sensor and transporter is GLUT2 
(Inagaki et al., 1992) and by means unknown, GLUT2 functions become impaired and 
beta-cell does not take up glucose or release insulin and the outcome is hyperglycemia 
(Inagaki et al., 1992; Catalano et al., 2003). 
1.1.4 Complications of DM 
DM has many associated complications, some of which are specific to the form of 
DM, and some of which are common among all three types (Canadian Diabetes 
Association, 2008). One of the most common complications of TID and a leading cause 
of hospitalizations is ketoacidosis, which occurs if an individual fails to administer a 
sufficient amount of insulin (Berg, 1986). Complications that are common among 
individuals with DM regardless of the type are neuropathy (nerve disease), nephropathy 
(kidney disease), endothelial dysfunction and hypertension (high systemic arterial blood 
pressure) (Canadian Diabetes Association, 2008). No matter the type of complication, 
the side effects can be very serious and even deadly (Canadian Diabetes Association, 
2008). 
12 
Ketoacidosis 
Ketoacidosis is a condition which affects individuals with T1D, although there 
have been rare cases of individuals with T2D with the condition (Berg, 1986). With 
inadequate administration of exogenous insulin (a common treatment for T ID discussed 
below in the section titled Pharmacological Treatment Options for DM), glucose cannot 
be used to produce the energy compounds needed to fuel the body. To review, insulin 
increases the number of glucose transporters (GLUT4s) on the muscle cell membrane that 
are responsible for glucose entry into the cell (Klip & Paquet, 1999). Without insulin, the 
increase in GLUT4s does not occur (Klip & Paquet, 1999) and inadequate glucose is 
transported into the cell therefore, the body needs to rely on another source to create 
energy compounds (such as ATP) that will be use in bodily processes. The alternative 
energy sources are ketone bodies (Fery & Balasse, 1985). 
Ketone bodies are created in the liver and are used as a source of fuel when the 
muscle cells are unable to use glucose in glycolysis and the Kreb's cycle for fuel (Fery & 
Balasse, 1985). Specifically, the liver acquires acetyl coenzyme A (acCoA) from the 
oxidation of fatty acids and two molecules of acCoA are acted upon by the enzyme 
thiolase to form acetoacetyl coenzyme A which is eventually converted into the ketone 
body acetoacetate (Hird & Symons, 1962). Acetoacetate can enter the blood stream as 
itself, but it can also undergo reactions to form two other ketone bodies called beta-
hydroxybutyarate and acetone (Lopes-Carodoso et al., 1975). All three ketones enter the 
blood stream, acetone travels to the kidneys to be expelled in urine and the former two 
travel to the muscle cell (Hird & Symons, 1962). Inside the muscle cell, the ketone 
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bodies are converted into acCoA to be used in the Kreb's cycle to produce ATP, depicted 
in Figure 8. 
If the ketone bodies are produced faster than they are catabolized or taken up by 
the muscle cells, they begin to accumulate in the blood stream (to bring the blood pH 
below 7.2) and ketoacidosis occurs (Fery & Balasse, 1985). An individual with 
ketoacidosis may feel thirsty and/or nauseous, have abdominal pain, display frequent 
urination and have acetone breath (sweet, fruit-like smelling breath) (Chiasson et al., 
2003). Ketone bodies are strong acids and their accumulation can disrupt any 
physiological function ultimately leading to death if untreated (Chiasson et al., 2003). 
Ketoacidosis can be treated with intravenous insulin administration (Chiasson et al., 
2003). 
Neuropathy 
Neuropathy is a disorder arising from nerve damage (Canadian Diabetes 
Association, 2008). There are four types of diabetic neuropathies: peripheral (affects 
legs, feet, toes, arms, hands and fingers), autonomic (affects heart rate, blood pressure, 
perspiration, and digestive, bowel, bladder and sexual function), proximal (affects thighs, 
hips and buttocks) and focal (affects a single nerve or group of nerves causing localized 
muscle weakness) (National Institute of Diabetes and Digestive and Kidney Diseases, 
2009). Peripheral neuropathy is the most common type of neuropathy in DM and the 
popular sites of nerve damage are the ulnar, peroneal (fibular) and tibial nerves which 
lead to loss of sensation and uncomfortable pain in the wrists and feet (Dyck & Thomas, 
1999; National Institute of Neurological Disorders and Stroke, 2008). Neuropathy takes 
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several years to develop and it is a condition with many pathologies and etiologies 
(Vinik, Strotmeyer, Nakave, & Patel, 2008). With respect to the diabetic population, it is 
believed that neuropathy is caused by hyperglycemia and dyslipidemia (Vinik et al., 
2008). Hyperglycemia and dyslipidemia cause peripheral arterial disease (PAD), which 
itself is a complication of DM (and will be discussed below in Peripheral Arterial 
Disease (PAD)), but one which reduces blood flow and increases hypoxia (lack of 
oxygen) to the nerves causing damage (Vinik et al., 2008). There is no true treatment for 
neuropathy, but affected individuals can wear properly fitted shoes and take analgesics to 
reduce pain (National Institute of Neurological Disorders and Stroke, 2008). 
Nephropathy 
Nephropathy is the term used to describe kidney disease (Canadian Diabetes 
Association, 2008). Kidney disease describes a collection of pathologies that prevent the 
kidney from performing its filtering and blood pressure regulation functions causing 
wastes and excess fluids to remain in the body (The Kidney Foundation of Canada, 
2009c). Almost half of all individuals with nephropathy also have DM (Canadian 
Diabetes Association, 2008). Although kidney disease has many causes, 
glomerulosclerosis (thickening of the tiny blood vessel walls of the kidney) is the most 
common cause in DM (Kalant, 1978). In a normal kidney, blood filtering occurs in the 
glomerulus (a collection of capillaries) where blood pressure (BP) forces water and small 
molecules out of the capillaries, into the nephron tubule and out of the kidneys as urine, 
leaving larger and much needed molecules such as red blood cells and protein to continue 
circulating throughout the blood (Campbell et al., 2009). Glomerulosclerosis causes 
damage to the blood vessel walls and allows for the large proteins to be forced out of the 
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capillaries and into the nephron and it compromises waste filtering (Kalant, 1978). 
Along with compromised waste filtering, there is poor resting arterial BP regulation 
because the kidney damage creates a situation where excess water that is to be expelled 
as urine re-enters blood circulation (Kalant, 1978). The first indication of kidney disease 
is proteinuria (excess protein in the urine >30mg/day) (Canadian Diabetes Association, 
2008). The damage and thickening of the vessel walls in the glomerulosclerotic 
condition is associated with hyperglycemia (Kalant, 1978). The increase in vessel wall 
thickening is proportionate to increases in blood glucose concentration (Kalant 1978). 
Treatment options for kidney disease include dialysis and transplantation. With 
dialysis, a machine withdraws blood from the body and passes it through a dialyzer (an 
artificial kidney) (The Kidney Foundation of Canada, 2009a). The dialyzer contains 
dialysis fluid that is responsible for removing waste products from the blood (The Kidney 
Foundation of Canada, 2009a). A day dialysis treatment session can take up to 5 hours 
and most individuals receive 3 treatments per week (The Kidney Foundation of Canada, 
2009a). Nocturnal dialysis treatments (offered separately from day dialysis treatments) 
take place while the individual is asleep and there are usually 6-7 treatment sessions each 
week (Pierratos, 1999). The second treatment option for kidney disease is 
transplantation. Transplantation involves removing affected kidneys and replacing them 
with healthy kidneys from either a live or recently deceased donor. Kidney transplants 
have a success rate of 85-95% (The Kidney Foundation of Canada, 2009b). 
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Endothelial Dysfunction 
In DM, it is thought that hyperglycemia and dyslipidemia contribute to the 
dysfunction of the vascular endothelium (Canadian Diabetes Association, 2008). The 
endothelium is a type of simple squamous epithelium that lines the heart and blood 
vessels. The endothelium functions to regulate vascular tone (the degree to which a 
blood vessel is vasoconstricted or vasodilated), control thrombogenic processes (prevent 
the formation of blood clots and influence the degradation of them) and control 
inflammatory processes (such as platelet adhesion to blood vessel walls) (Ehrman, 
Gordon, Visich, & Keteyian, 2009). In a healthy endothelial cell, nitric oxide is produced 
and transported into vascular smooth muscle cells (VSMC) where it acts as the prominent 
agent for vasodilation, depicted in Figure 9. The process of nitric oxide formation begins 
with a receptor located on the endothelial cell membrane (Boger et al., 1998). The 
receptor is coupled with acetylcholine, bradykinin or acted upon by shear stress (from 
increased blood flow) and this stimulates an increase of calcium in the cytosolic space 
(Hayden & Tyagi, 2002). The increase in calcium activates the enzyme nitric oxide 
synthase (eNOS) which reacts with oxygen and this action allows for the co-factor 
tetrahydrobiopterin to couple another co-factor, nicotinamide adenine dinucleotide, to L-
arginine to form nitric oxide and L-citruilline (see Figure 10) (Boger et al., 1998). The 
effects of nitric oxide are counterbalanced by the production and release of 
vasoconstricting substances, the most powerful one of which is endothelin 1 (ET-I) 
(Morris & Jardine, 2000). ET-I acts on VSMC to induce vasoconstriction via endothelin 
A receptor activation. In contrast, it also acts as a negative feedback mechanism by 
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stimulating endothelin B receptors and triggering the release of nitric oxide (Morris & 
Jardine, 2000). 
Endothelial dysfunction occurs when there are alterations in the expression and/or 
release of vasoactive, anti-growth, anti-inflammatory and/or anti-thrombotic substances 
(Faulx, Wright, & Hoit, 2003), thus preventing the endothelium from properly carrying 
out its function (Avogaro, Fadini, Gallo, Pagnin & de Kreutzenberg, 2006). In DM and 
other cardiovascular diseases, endothelial dysfunction is believed to occur as a result of 
reduced nitric oxide bioavailability, increased reactive oxygen species (ROS; highly 
reactive oxygen ions that can damage cell structures) and/or atherogenesis (formation of 
fatty deposits on the inner lining of the arteries) (Ding & Triggle, 2005). With respect to 
the former, potential causes of reduced bioavailability include 1) reduced L-arginine 
concentrations, 2) the down-regulation of eNOS, 3) impaired eNOS activation, and 4) 
increased oxidative stress/ROS-induced nitric oxide degradation (discussed below) 
(Faulx et al., 2003). 
In addition, hyperglycemia and dyslipidemia cause an increase in protein arginine 
N-methyltransferase activity (Nash, 2002). Protein arginine N-methyltransferase is the 
enzyme responsible for the formation of assymetrical dimethylarginine (ADMA). 
ADMA is an inhibitor of L-arginine (Nash, 2002). With L-arginine deficiency, the 
nicotinaminde adenine dinucleotide reacts with oxygen instead of the L-arginine and a 
superoxide, instead of nitric oxide, is produced (Hayden & Tyagi, 2002). This form of 
dysfunction has the endothelial cell producing less nitric oxide and in turn decreases 
vasodilation and blood flow, and increases vasoconstriction and blood pressure (Boger et 
al., 1998). Also, the formation of superoxides instead of nitric oxide is detrimental to all 
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cells because superoxides react with transition metals (i.e., iron) to form hydrogen 
peroxide and then a hydroxyl radical, or they react with nitric oxide (formed in a separate 
cell) to form peroxynitrite (see Figure 11) (Beckman & Koppenol, 1996; Turrens, 2003). 
The hydroxyl radical and peroxynitrite are known as (ROS) and they react with nucleic 
acids and proteins altering their functions and contributing to endothelial dysfunction 
(Beckman & Koppenol, 1996). 
Endothelial dysfunction can also be caused by diabetic dyslipidemia itself. 
Diabetic dyslipidemia increases the risk of developing atherosclerosis (fatty deposits on 
the inner lining of the arteries) by three-fold (Kannel & McGee, 1979). In the diabetic 
dyslipidemic condition, readily available and over abundant LDLs are taken up by the 
endothelial cells where they are acted upon by ROS and the enzymes sphingomyelinase, 
secretory phospholipase and myeloperoxidase to create oxidized LDLs which are pro-
inflammatory lipids that attract certain monocytes (white blood cells) called macrophages 
(Rose & Afanasyeva, 2003; Rader & Daugherty, 2008). The macrophages take in 
oxidized LDLs through the scavenger receptors CD36 and SR-A to form lipid-laden foam 
cells (see Figure 12) (Rader & Daugherty, 2008). The foam cells migrate to the 
endothelial wall where they create a pro-inflammatory environment by producing 
cytokines that signal intimal (endothelial lining of the blood vessel or lumen) 
proliferation and the production of myeloperoxidase, an enzyme that produces ROS, 
which leads to more foam cell production and further endothelial damage (as ROS 
disrupt nucleic acids and proteins) (Rader & Daugherty, 2008). The foam cells also 
collect cholesterol and platelets, and can develop into a lesion or plaque that narrows the 
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lumen and contributes to endothelial dysfunction, hypertension and/or reduced blood 
flow (Rader & Daughtery, 2008). 
Endothelial cell damage and the resultant dysfunction is thought to be a major 
contributor to the development and progression of cardiovascular disease (Ehrman et al., 
2009). The term cardiovascular disease encompasses several disease states that affect the 
heart or blood vessels, such as coronary artery disease (including atherosclerosis 
(thickening of arterial walls due to fatty deposits), angina and myocardial infarction), 
hypertension, PAD (including atherosclerosis), rheumatic heart disease (damage to the 
heart muscle and heart valves caused by bacteria), congenital heart disease 
(malformations of the heart present at birth) and heart failure (World Health 
Organization, 2009b). The first, coronary artery disease is often used interchangeably 
with the term cardiovascular disease and/or atherosclerosis, as not only is it the most 
prominent form of cardiovascular disease, atherosclerosis predominantly occurs in the 
coronary arteries (World Health Organization, 2009b). When the atherosclerosis occurs 
in the arteries leading to the brain it is referred to as either carotid artery disease or 
cerebrovascular disease, depending on the location of the atherosclerosis, and finally as 
PAD when referring to the arteries outside of the heart and brain (American Heart 
Association, 2008b). Atherosclerosis is the leading cause of cardiovascular disease 
(Canadian Diabetes Association, 2008). 
Hypertension 
Hypertension, characterized by a sustained elevation in resting BP that is equal to 
or above 140 mmHg(systolic) and/or 90 (diastolic) mmHg, affects most individuals with 
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diabetes (Canadian Diabetes Association, 2008). Systolic BP represents the pressure 
acting against the arterial walls as blood is ejected from the heart and its contracting 
ventricles, while diastolic BP represents the pressure acting against arterial walls when 
the heart's ventricles are relaxing and filling with blood (Powers & Howley, 2009). As 
previously discussed, one cause of hypertension in diabetics is the loss of regular kidney 
function which regulates BP (Kalant, 1978). As BP is dependent on volume, the 
accumulated, excess water re-enters the circulation and increases BP (Kalant, 1978). The 
pressure increase also influences the progression of kidney disease because it causes 
more force to be exerted on blood vessel walls which contributes to their damage (Kalant, 
1978). When the blood vessels of the kidneys are damaged, the kidneys cannot function 
properly and their pathology progresses at a faster rate (Kalant, 1978). 
Resting BP is also dependent on vascular resistance (resistance to blood flow 
provided by blood vessels). In the diabetic condition, increased vasoconstriction is 
caused by increased levels of the enzyme protein kinase C due to hyperglycemia (Koya & 
King, 1998). An individual with hyperglycemia will still exhibit glucose uptake by cells 
using the glucose transporter proteins (Klip & Paquet, 1999), yet it is not sufficient 
enough to reduce blood glucose levels. It is, however, sufficient enough to increase 
levels of protein kinase C (Koya & King, 1998). Glucose enters the cell and is converted 
into dihydroxyacetone phosphate (DHAP) via glycolysis (Koya & King, 1998). DHAP is 
acted on by the enzyme glycerol-3-phospate dehydrogenase to form glycerol-3-phosphate 
(Koya & King, 1998). Glycerol-3-phophate goes through a series of reactions to form 
diacylglycerol (see Figure 13) (Yoshimura, Oshima, & Ogasawara, 2007). After 3-5 days 
of hyperglycemia, there is a noticeable and significant increase in diacylglycerol 
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concentration (Koya & King, 1998). Diacylglycerol activates protein kinase C which is 
responsible for increased calcium responsiveness in smooth muscle contraction 
(vasoconstriction) (see Figure 14) and increased smooth muscle contraction itself (Koya 
& King, 1998). 
Another probable cause of increased vascular resistance in the diabetic condition 
is smooth muscle cell proliferation due to increased mitogen-activated protein kinase 
(MAPK) activation (Bruemmer, 2006). Hyperinsulinemia (in T2D) causes increased 
MAPK activity (Bruemmer, 2006). In the healthy condition, insulin binds to the insulin 
receptor on the cell membrane and the phophotidylinositol-3 kinase (see Negative 
Feedback and Blood Glucose Regulation Mechanisms) pathway is activated (Robinson 
& Buse, 2008). In an individual with T2D, the phophotidylinositol-3 kinase pathway is 
inhibited and instead the MAPK pathway is activated (see Figure 15) (Bruemmer, 2006). 
The insulin binds to the insulin receptor and this action causes the activation of the 
enzyme tyrosine kinase which phosphorylates insulin receptor substrate proteins 
(Robinson & Buse, 2008). The activated insulin receptor substrate proteins then bind to 
the Src homology 2 protein and the two proteins interact with another protein (growth 
factor receptor bound protein 2) and all three proteins bind to the Ras guanylnucleotide 
exchange factor son of sevenless to create a protein complex (Kusari, Byon, 
Bandyopadhyay, Kenner, & Kusari, 1997). The activated protein complex removes 
guanosine diphosphate from Ras, after which Ras binds to guanosine triphosphate and 
becomes activated (Kusari et al., 1997). Activated Ras activates Raf protein kinase 
which activates mitogen-activated protein kinase kinase, after which MAPK is then 
activated (Kusari et al., 1997). MAPK is responsible for smooth muscle cell 
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proliferation (Bruemmer, 2006). Increased smooth muscle cell mass increases vascular 
resistance because more cells are available to induce vasoconstriction (Koya & King, 
1998). 
The adoption of a healthy lifestyle, including weight loss strategies, sodium 
restriction and regular physical activity, is an integral component of hypertension 
treatment and management in DM. A decrease of 1 kilogram in body weight has been 
proven to decrease mean BP (calculated as [resting diastolic BP + 0.33 x (systolic BP-
diastolic BP)]) by 1 mmHg. Furthermore, reductions in dietary sodium intake to less than 
2300 mg per day is associated with systolic BP and diastolic BP reductions of 5 mmHg 
and 3 mmHg, respectively. (American Diabetes Association, 2002) 
For many individuals, pharmacological therapy is required in addition to lifestyle 
modifications to reduce resting BP to values within the target range. Drug therapy for 
individuals with DM and hypertension includes a combination of angiotensin converting 
enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers and diuretics. 
(Canadian Diabetes Association, 2008) 
1.1.5 Recommendations for the Treatment of DM 
Exercise 
Exercise training is a non-pharmacological, non-surgical treatment recommended 
for DM (American College of Sports Medicine, 2010). Exercise, and thus the 
components of an exercise training program, can be aerobic or anaerobic in nature. 
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Exercise is considered aerobic when performed at <70% of maximum heart rate 
(Conners, Grymkowski, Kimber, & Reynolds, 1992). Aerobic exercise uses both 
carbohydrates and fats as a fuel source (Powers & Howley, 2009), and ATP is created via 
the Kreb's cycle (see Figure 3) and the electron transport system (see Figure 4). 
In general, anerobic exercise is performed at an intensity of >75% of an 
individual's maximum heart rate (Conners et al., 1992), and ATP is produced from 
glycolysis (see Figure 2) and the phosphagen energy system (see Figure 16) in the 
absence of oxygen (Conners et al., 1992). Although resistance exercise is classified as a 
type of anaerobic exercise, it applies a force of resistance against the force of contraction 
(Conner et al., 1992), and is, as such, not driven by maximal heart rate. There are three 
different types of resistance exercises: concentric (shortening of muscle fibers due to 
greater muscle force than resistance force), eccentric (lengthening of muscle fibers due to 
greater resistance force than muscle force) and isometric (no change in fiber length due to 
the resistance force and muscle force equaling one another) (Heyward, 2006; Hamill & 
Knutzen, 2003). Isometric exercise is often distinguished separately from concentric and 
eccentric resistance exercise because of its unique resistance force and lack of fiber 
length change. 
In general, both aerobic and anaerobic exercise training regimens have shown to 
improve tissue insulin sensitivity (how well muscle cells respond to insulin) in those with 
DM (Winnick et al., 2008; Jimenez, Santiago, Sitler, Boden, & Homko, 2009). 
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Improved insulin sensitivity 
Although T1D is characterized by insulin inavailability, sensitivity to existing 
insulin is increased with chronic, but not acute, exercise exposure in this population. For 
example, Jimenez and colleagues (2009) saw no change in pre- to post-exercise insulin 
sensitivity in adults with T1D (n=14) who performed 5 sets of 6 repetitions of a 
resistance leg exercise at 80% of 1 repetition maximum (Jimenez et al., 2009). In 
contrast, 12 weeks of aerobic exercise training (3 times per week for 45 minutes) at 80-
75% maximum heart rate intensity increased insulin sensitivity by 25+/- 5% in children 
(n=15) with T1D (Landt, Campaigne, James, & Sperling, 1985). 
Individuals with T2D have a lower insulin sensitivity than their T1D counterparts 
(Weir & Bonner-Weir, 2004) and their reaction to exercise differs as well. The positive 
effect of exercise on insulin sensitivity in T2D is noticeable after both acute and chronic 
exercise. In a population of T2D (n=9), a single bout of exercise performed for 15 
minutes at anaerobic threshold intensity can increase glucose infusion rate (an index of 
insulin sensitivity) by 3.2+/-0.8 mg/kg/min (Oguri, Adachi, Ohno, Oshima, & 
Kurabayashi, 2009) immediately post-exercise. These findings were further supported by 
Winnick and colleagues (2008) who observed increases in whole-body insulin sensitivity 
after one week of exercise. Specifically, 18 obese T2D individuals performed 50 minutes 
of treadmill aerobic walking (at 70% of maximal oxygen uptake) everyday for 7 days, 
and post-training increases in glucose infusion rates of 0.2+/- 0.3 mm/kg/min were noted 
(Winnick et al., 2008). 
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The exercise data on GD and insulin sensitivity and resistance are limited and 
equivocal. With respect to the effect of acute exercise, a study conducted by Garcia-
Patterson and colleagues (2006) examining 20 non-exercise trained women with GD who 
performed a self-paced flat surface walking bout for 1 hour found decreases (0.7+/- 0.9 
mM) in 1 hour postprandial blood glucose, when the women served as their own controls 
the day prior (Garcia-Patterson et al., 2006). A second study (n=33) comparing women 
with GD who exercise trained (30 minutes, 4 days per week, 12 weeks, 70% maximal 
oxygen uptake) to those who were sedentary observed no differences in insulin 
sensitivity, insulin resistance or blood glucose concentration between the two groups 
(Avery, Leon, & Kopher, 1997). The authors did, however, report modest, but not 
statistically significant, increases in cardiovascular fitness. 
Aerobic and anaerobic (including resistance) exercise not only increases insulin 
sensitivity and improves insulin resistance in T1D, T2D and GD, evidence suggests that 
individuals with T2D will exhibit improvements in GLUT4-driven glucose regulation 
with exercise (Kennedy et al., 1999). 
Improved blood glucose regulation in T2D: GLUT4s and their translocation 
As previously discussed, glucose transporter proteins (GLUT4s) are needed for 
the uptake of glucose by the muscle cells (Klip & Paquet, 1999). GLUT4 translocation 
can be insulin-stimulated, but it can also be contraction (or exercise) stimulated (Hardie, 
2002). Acute aerobic exercise (one session of cycling at 60-70% maximal oxygen uptake 
for 45-60 minutes) performed by adults with T2D elicited a 77% increase in membrane 
GLUT4 when compared to the resting condition (Kennedy et al., 1999). 
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Exercise-induced increases in GLUT4 have also been noted in individuals with 
T2D following resistance exercise training. Holten and colleagues (2004) examined 10 
individuals with T2D who served as their own control for a resistance exercise study. 
Participants completed 3 different unilateral leg exercises (3 sets, 8-12 repetitions at 70-
80% of 3 repetition maximum), 3 times per week for 6 weeks (Holten et al., 2004). After 
the intervention, GLUT4 density was increased by approximately 40% in the trained legs 
when compared to the untrained (control) legs (Holten et al., 2004). The trained legs also 
displayed an increase in thigh circumference (52.5+/-1.5 cm to 54.3+/-1.9 cm) and 
muscle fiber diameter (5.4+/-1.7%) (Holten et al., 2004). 
The contraction-stimulated GLUT4 translocation mechanism follows a different 
pathway than that of the insulin-stimulated GLUT4 translocation (Kruth-Kraczek, 
Hirshman, Goodyear, & Windder, 1999). The insulin-stimulated pathway involves the 
insulin receptor and protein kinase B, while the contraction-stimulated pathway involves 
adenosine monophosphate-activated protein kinase (AMPK) (Robinson & Buse, 2008; 
Kruth-Kraczek et al., 1999). 
Exercise (aerobic and anaerobic) causes a change in the cellular energy status 
recognized by an increase in adenosine monophosphate concentration due to the 
breakdown of the fuel adenosine triphosphate (Kruth-Kraczek et al., 1999). The increase 
in adenosine monophosphate activates AMPK B which phosphorylates the protein 
AS 160, which is responsible for converting the Rab protein into its inactive form of 
guanosine diphosphate and inhibiting GLUT4 movement, and dissociates it from GLUT4 
located inside the muscle cell (Hardie, 2002). Once dissociated, AS 160 no longer 
promotes the Rab-guanosine diphosphate conversion and the Rab gets converted into its 
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active form, guanosine triphosphate which causes the translocation GLUT4 to the cell 
membrane (see Figure 17) (Klip & Paquet, 1999; Hardie, 2002). Although the activating 
mechanisms for GLUT4 translocation differ between insulin-stimulated and contraction-
stimulated situations, both pathways dissociate AS 160 from GLUT4 allowing it to be 
transported to the membrane (Hardie, 2002; Klip & Paquet, 1999). The increase in 
GLUT4s increases glucose uptake by the muscle cells and this reduces the elevated blood 
glucose concentration in T2D reducing the extent of hyperglycemia and its effects 
(decreased nitric oxide production and increased ROS production) (Klip & Paquet 1999). 
Exercise Recommendations 
In light of the above-described benefits of exercise in those with DM, exercise is a 
highly recommended treatment option, particularly for those with T2D. The gold 
standard exercise prescription guidelines, endorsed by the American College of Sports 
Medicine, recommend 20 to 60 minutes (which can be divided into 10 minute bouts for a 
total of 150 minutes per week) of dynamic aerobic activity at 50-75% of maximum heart 
rate, 3 to 7 times per week, supplemented with light weight training 2 to 4 days per week. 
The aerobic activity can include walking, running, swimming or cycling, for example, 
and light weight training refers to resistance training focusing on larger muscle groups 
with weights ranging between 60-80% of 1 repetition maximum for at least 2 sets of 8-12 
repetitions. (American College of Sports Medicine, 2010) 
Pharmacological Treatment Options for DM 
Those with T1D require exogenous insulin daily to control blood glucose 
concentration (Berg, 1986). This exogenous insulin is synthetically engineered and 
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produced, and can be injected into the body using a syringe (a needle and vial system), an 
insulin pen (pre-filled with insulin and dosage-controlled via a dial) or an insulin pump 
(delivers short-acting insulin throughout the day using a catheter placed under the skin) 
(Canadian Diabetes Association, 2008). 
Individuals with T2D can treat or control their decreased insulin sensitivity with 
the use of oral medications. Thiazolidinediones and biguanides increase the body's 
insulin sensitivity. Sulfonylureas and meglitinides stimulate the pancreas to synthesize 
more insulin. These drugs, in turn, help lower blood glucose, and some can be combined 
to elicit a greater response, but the risk of side effects increases with their combination 
(Canadian Diabetes Association, 2008). 
Expectant mothers with GD, when necessary, can be prescribed insulin for 
injection without harming the fetus (Canadian Diabetes Association, 2009). 
1.2 Peripheral Arterial Disease in DM 
1.2.1 Peripheral Arterial Disease (PAD) 
As previously discussed, peripheral arterial disease (PAD) is a common 
complication of DM and is characterized by structural changes (such as inflammation or 
tissue damage) in the blood vessels outside of the heart and brain, and these changes 
cause reduced blood flow to the tissues (American Heart Association, 2009b). The most 
common symptom of PAD is intermittent claudication which is described as pain or 
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cramping in the muscles of the lower extremities brought on by walking and relieved by 
rest, yet some diabetics are asymptomatic due to their neuropathy-induced loss of 
sensation (American Diabetes Association, 2003). PAD affects individuals with DM 
mainly in the popliteal and tibial arteries (below the knee) (American Diabetes 
Association, 2003). DM-associated hyperglycemia and dyslipidemia are two main causes 
of PAD (American Diabetes Association, 2003). PAD is also an underlying cause of 
other diabetic conditions such as neuropathy and nephropathy (Kalant, 1978; Vinik et al., 
2008). 
1.2.2 Methods of Assessing PAD 
There are many ways to measure and assess PAD, including the most widely 
employed methods of angiography, ankle-brachial index and duplex ultrasound. 
Catheter angiography, also known as conventional angiography, is a minimally 
invasive test and the gold standard for PAD assessments (Radiological Society of North 
America, 2010; Clifton, 2000). A catheter containing a contrast dye is inserted into an 
artery through an incision in the skin after which the artery undergoes an x-ray 
(Radiological Society of North America, 2010; Clifton, 2000). Catheter angiography is 
the most accurate form of PAD assessment; however, it is associated with several risks 
such as infections and kidney damage (Radiological Society of North America, 2010). 
Phased-contrast magnetic resonance angiography non-invasively assesses PAD. 
Various magnetic fields are applied to the limb or body part in question. Several images 
are acquired and a mathematical pixel by pixel calculation is applied to phase out static 
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tissues (muscle and bone) leaving only the flowing blood visible on the final image. 
Similar to catheter angiography the final image can be used to detect arterial narrowings 
and malformations, but unlike the gold standard method, phased-contrast angiography 
can also measure blood flow. However, this method of assessment is time consuming 
and adversely affected by slight movements made by the individual undergoing the 
angiography. (Clifton, 2000) 
The ankle-brachial index (ABI) is another non-invasive test used to assess PAD, 
and involves the measurement of ankle systolic BP (using dorsalis pedis and posterior 
tibial arteries) and arm systolic BP (using the brachial artery) to ultimately evaluate the 
patency of the arteries of the lower extremities (Bernstein & Fronek, 1982). Specifically, 
a ratio (ABI) between the ankle and arm is determined from the measured systolic BPs 
(e.g., ankle systolic BP/ brachial artery BP) (Bernstein & Fronek, 1982). For the 
calculation, the greater value of the two brachial pressures is used, and both ankle 
pressures (on each leg) are used to give a total of 4 ABIs per individual (Bernstein & 
Fronek, 1982). A normal, non-diseased lower extremity artery will have an ABI >0.90 
while a diseased artery will have an ABI of <0.90 (Carbayo et al., 2007). To further 
classify PAD, an ABI of 0.70-0.89 suggests a mild obstruction in the artery, 0.40-0.69 
suggests a moderate obstruction, and <0.40 suggests a severe obstruction (American 
Diabetes Association, 2004d). The ABI test has been validated against angiographically 
confirmed disease (accuracy range: 95-100%) (Bernstein & Fronek, 1982). One 
limitation of the ABI is the influence of poorly compressible and calcified vessels. In 
such instances, BP measurements cannot be obtained as a result of the arteries' inability 
to occlude, leading to artefactually elevated ABIs of >1.30 (Bernstein & Fronek, 1982). 
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Another limitation is that aortoiliac stenoses (abnormal narrowing of the aorta or iliac 
arteries) can reduce BP in the lower extremity (and in turn reduce the ABI) causing the 
false belief that the PAD is solely in the lower extremity (American Diabetes 
Association, 2004). Even with these limitations, ABI is a highly used, popular and 
proven non-invasive method of PAD assessment in clinical settings (American Diabetes 
Association, 2004). 
Another method of assessing PAD is duplex ultrasound which uses a combination 
of two techniques to obtain arterial images and determine the degree of the disease 
(Scottish Intercollegiate Guidelines Network, 2006). Images are acquired through both 
B-mode ultrasound (using sound frequencies to produce an arterial image) and Doppler 
ultrasound (using reflected sound waves to generate an image of blood flow direction and 
velocity) and assessed together (Scottish Intercollegiate Guidelines Network, 2006). B-
mode ultrasound provides a visual image of arterial narrowings, while Doppler 
ultrasound uses blood flow and velocity to determine the amount (in percent) of 
anatomical narrowing (Sensier et al., 1996). Duplex ultrasound has been proven to 92-
99% accuracy when compared to angiography (Aly et al., 1998). 
In addition to the assessment of PAD itself, the symptoms of the disease can be 
evaluated. A common practice is the assessment of intermittent claudication using a 
graded-exercise treadmill test (Gardner, Skinner, Cantwell, & Smith, 1999). There are 
different protocols for the graded-treadmill test, a popular one of which is the Gardner 
protocol (Gardner et al., 1999). Using the Gardner protocol, individuals walk on the 
treadmill at a constant 2 mph, beginning at 0% grade, with a 2% increase in grade every 2 
minutes to a maximum of 14 % (completing the 2 minutes at 14% for a maximum total of 
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16 minutes on the treadmill) (Gardner et al., 1999). During the graded-exercise treadmill 
test, the distance at which the individual first notices claudication pain is recorded and 
this is referred to as the initial claudication distance (ICD) (Hiatt, Nawaz, Regensteiner, 
& Hossack, 1998). The absolute claudication distance (ACD), the distance at which the 
individual reaches maximal claudication pain causing the termination of the test, is also 
recorded (Hiatt et al., 1998). The graded-exercise treadmill test is used clinically across 
all age groups and disease states and has a within-subject variation of 15-25% for the 
ICD and 12-13% for the ACD (Hiatt et al., 1998). This test is superior to the previously 
popular constant-load treadmill test, where individuals walk at 2 mph at a constant grade 
of any value between 0% and 12% for a maximum of 5 minutes, which has a within-
subjects variation of 30% for the ICD and 45% for the ACD (Gardner et al., 1999). 
Increases in ICD and ACD with repeated graded-exercise treadmill tests correlate with 
improved ambulatory function (Hiatt, Regensteiner, Hargarten, Wolfel, & Brass, 1990). 
1.2.3 Treatment recommendations for PAD 
The most effective treatment and control methods for PAD are of the surgical 
nature, but medications and physical activity can control the prominent risk factors of 
PAD (i.e., hypertension and dyslipidemia) and slow or halt the progression of the disease 
as well (American Heart Association, 2009a). 
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Chronic Exercise and PAD in DM: A Closer Look 
Aerobic exercise training 
Although aerobic exercise bouts can be painful to individuals with PAD due to 
claudication effects (Gardner & Montgomery, 2008), aerobic exercise training can 
improve walking time and distance and delay the onset of claudication signifying a halt in 
the progression of the disease (Imparato, Kim, Davidson, & Crowley, 1975). For 
example, Hiatt and colleagues (1994) demonstrated that a 12 week treadmill training 
program (3 hours per week at an intensity sufficient to produce claudication) increased 
maximal walking time by approximately 74% in individuals with PAD. An additional 12 
weeks, using the same individuals performing the same exercise program, increased their 
maximal walking time by approximately another 49% (Hiatt, Wolfel, Meier, & 
Regensteiner, 1994). Upper extremity aerobic training programs appear to increase 
ambulatory function as well by improving maximal walking distance. For example, 
Treat-Jacobson and colleagues (2009) investigated 41 individuals with PAD (15 of whom 
had DM) performing supervised arm-ergometry exercises, treadmill walking or both for 
12 weeks (3 hours per week). Findings suggested that arm-ergometry performed for 60 
minutes (cycles of 2 minute cycling at 10 watts below maximum ability, followed by a 2 
minute rest period) increased maximal walking distance by approximately 53% (Treat-
Jacobson, Bronas, & Leon, 2009). Furthermore, treadmill walking for 60 minutes (cycles 
of 2 mph walking until claudication, followed by rest until pain relief) and a combination 
of both exercise programs increased maximal walking distance by 69% and 68%, 
respectively (Treat-Jacobson et al., 2009). Another study further supported these findings 
by concluding that after 24 weeks of bi-weekly upper and lower extremity aerobic 
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exercises (85-90% maximal oxygen uptake) individually increased maximal walking 
distance by approximately 30% (Zwierska et al., 2005). 
Resistance exercise training 
In addition to delaying the onset of claudication, individuals with PAD who 
undergo a resistance training program can reap muscular strength and aerobic endurance 
benefits. For example, Wang and colleagues (2009) implemented a maximal lower leg 
specific strength training program in individuals with PAD, whereby participants 
performed 4 sets of 5 repetitions (85-90% of 1 repetition maximum) on a leg press 3 
times per week for 8 weeks (Wang et al., 2009). The participants increased their 
muscular strength, as evidenced by an increase in their 1 repetition maximum by 
approximately 31% (Wang et al., 2009). Walking economy (the rate at which oxygen is 
consumed during a walking session) increased by approximately 9.7% (Wang et al., 
2009). Other studies using lower extremity resistance exercise training in PAD also 
found increases in ACD (increased approximately 36%) and maximal walking time 
(increased approximately 49%) (Hiatt et al., 1994; McDermott et al., 2009), as well as 
stair climbing endurance (increased approximately 15.0 points on a physical functioning 
test) (McDermott et al., 2009). 
Effects of aerobic and resistance exercise training on the pathophysiology of 
PAD 
PAD is, once again, the structural changes in arterial walls (usually inflammation) 
(American Heart Association, 2008b) influenced by dyslipidemia and characterized by 
endothelial dysfunction (American Heart Association, 2008a). The lack of progression of 
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PAD during an exercise regimen could be attributed to an alteration of an individual's 
lipid profile and improved endothelial function and vasodilation. 
Aerobic and resistance exercise lowers triglyceride levels through a process 
known as lipolysis by breaking down triglycerides into free fatty acids that can be used 
for fuel. Lipolysis is activated with increased sympathetic nervous system (a branch of 
the autonomic nervous system that increases its activity during exercise and stress) 
stimulation which in turn promotes the release of norepinephrine which stimulates 
receptors on adipose and/or skeletal muscle tissue. The binding of norepinephrine to 
these receptors activates the enzyme adenyl cyclase which converts adenosine 
triphosphate into the cyclic adenosine monophosphate that is responsible for activating 
protein kinase A. Activated protein kinase A phosphorylates hormone sensitive lipase 
which acts on triacylglycerol (triglyceride). A series of lipase reactions occur and the 
compound which was once triacylglycerol is now a glycerol molecule and three free fatty 
acid molecules (see Figure 18). The lipolysis causes the triglyceride levels to decrease 
and creates fuels that can be used for energy. (Large & Arner, 1998; Lafontan et al., 
2008) 
The lowered triglyceride levels cause an increase in HDL activity which is 
already initially increased due to exercise (Dishman, Washburn, & Heath, 2004). 
Exercise is known to increase the activity of the enzyme that works in conjunction with 
HDL, lecithin cholesterol acyl transferase (LCAT) (Dishman et al., 2004). HDL is 
created when apolipoprotein Al (APOA-1) binds with phospholipids (from membranes) 
and cholesterol (from diet) that have exited a cell using a protein transporter called 
adenosine triphosphate-binding cassette transporter (ABC) (it relies on energy from 
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adenosine triphosphate to work) (Ikonen, 2008). This HDL is acted on by LCAT, from 
the interstitial space, which esterifies the cholesterol to form globular (sphere-shaped) 
HDL (Ikonen, 2008). The globular HDL accepts and esterifies cholesterol from other 
tissues, arterial walls and LDLs with the help of LCAT (Ikonen, 2008). The globular 
HDL can travel to liver cells or steroidogenic cells where the esterified cholesterol is 
removed using a scavenger receptor and then excreted as bile or used in hormone 
synthesis (see Figure 19) (Ikonen, 2008). As exercise increases LCAT activity, HDL 
production and activity increase and LDL levels decrease (Borer, 2003). 
The exercise-induced improvements in PAD and endothelial function are thought 
to occur primarily through increased nitric oxide production (Sessa, Pritchard, Seyedi, 
Wang, & Hintze, 1994) via a shear stress mechanism (Hambrecht et al., 1998; Sessa et 
al., 1994), yet changes in resistance vessel structure and/or improved sensitivity of the 
peripheral vasculature cannot be ruled out. During aerobic exercise, cardiac output 
(product of heart rate and stroke volume) increases approximately 4-fold in order to meet 
the blood and oxygen demands of the working muscles, and this causes repeated episodes 
of vascular wall shear stress (Sessa et al., 1994). The mechanical shear stress of blood 
(along with acetylcholine and bradykinin) is a stimulus (Hayden & Tyagi, 2002) that acts 
on endothelial cell receptors triggering an increase in cytosolic calcium which activates 
the eNOS to produce nitric oxide (Borer et al., 1998; Grijalva et al., 2008). Resistance 
exercise also increases the amount of blood circulating to the muscle tissue causing an 
increase in shear force and thus an improvement in endothelial dysfunction (Sessa et al., 
1994). 
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Isometric exercise training 
To date, no studies have examined the chronic effects of isometric exercise on 
ICD, ACD and blood flow in individuals with PAD. However, as PAD is characterized 
by intermittent claudication and the subsequent decrease in blood flow, studies examining 
blood flow and endothelial function (including vasodilation) with isometric exercise 
training are applicable to this clinical population. Blood flow is determined by the 
product of (7ir~)v, ('r' refers to the radius of the blood vessel, V refers to the velocity of 
the blood), and thus an increase in blood vessel radius (such as vasodilatory ability) 
promotes an increase in blood flow. 
Isometric exercise is novel form of exercise that is relatively under-investigated, 
especially in clinical populations. Although the effect of both acute and chronic lower 
extremity isometric exercise on blood flow is limited, studies have examined blood flow 
post-acute isometric exercise in the arm. Thompson and colleagues (2007) observed a 
change in blood flow immediately following one isometric hand grip (IHG) session 
performed until the participant could no longer sustain the force within 5% of the target 
value (20% MVC) for more than 2 seconds. The participants, male (n=18) and female 
(n=20), displayed an increase in brachial blood flow from approximately 2 ml/min/100ml 
to 6.7 ml/min/lOOml and 7.4 ml/min/lOOml, respectively (Thompson, Fadia, Pincivero, & 
Scheuermann, 2007). The findings supported the work of McGowan and colleagues 
(2006) who noted an increase in brachial artery blood flow immediately following an 
acute bout of 30% MVC IHG exercise in individuals with hypertension (n = 17; 4, 2-
minute IHG contractions, each separated by a 4-minute rest period). An earlier study 
conducted by Lind & Williams (1979) found a positive linear relationship between IHG 
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intensity and forearm blood flow (2 seconds after the completion of the contraction) with 
7 individuals performing the exercises at 20%, 40% and 60% MVC. The linear 
relationship no longer existed at intensities >60% MVC, therefore the authors concluded 
that high intensities were not beneficial for increasing blood flow (Lind & Williams, 
1979). 
Although, acute bouts of isometric exercise have shown to increase post-exercise 
blood flow, they have also been associated with attenuation in endothelium-dependent 
vasodilation (McGowan et al., 2006a). The increase in blood flow and subsequent 
decrease in endothelium-dependent vasodilation has also been shown to occur with 
chronic upper extremity isometric training as in another study conducted by McGowan 
and colleagues (2006) where IHG was performed 3 times per week for 8 weeks. Chronic 
upper extremity isometric exercise training is associated with an increase in resting 
vasodilatory capacity and post-exercise blood flow (McGowan et al., 2006a), however, 
when compared to an acute bout, neither the magnitude of the increase in post-exercise 
blood flow is augmented, nor the transient reduction in endothelium-dependent 
vasodilation is ameliorated. 
The likely cause of reduced NO-mediated or endothelial-dependent arterial 
vasodilation is peroxynitrite formation from a reaction between NO and reactive oxygen 
species (ROS) (Li & Fostermann, 2000), which are created during ischemic conditions 
(Alessio et al., 2000) such as isometric exercise. This phenomenon of increased blood 
flow/decreased endothelial function could be due to an accumulation of metabolites, such 
as adenosine (Costa & Biaggioni, 1998), that cause the dilation of blood vessels in order 
39 
to decrease their local concentration (Herlihy, Bockman, Berne, & Rubio, 1976) thus not 
requiring endothelial-dependent vasodilation. 
Bilateral lower extremity isometric training studies are few and limited. One study 
examined resting arterial blood pressure (BP) in 11 healthy individuals performing 4, 2 
minute contractions at 30% maximum voluntary contraction 3 days per week for 8 weeks 
and found that resting systolic and diastolic BP were reduced by approximately 4 mmHg 
and 3 mmHg, respectively (Wiles, Coleman, & Swaine, 2009). However, during 
isometric exercise performance BP has been known to increase. Increases in BP with 
isometric exercise are dependent on both the size of the muscle employed and the 
intensity of the contraction, and heart rate increases are exercise and intensity dependent 
(Ray & Carrasco, 2000). As such, the BP and heart rate increases during acute isometric 
bilateral lower extremity exercise may be of a magnitude great enough to elicit larger 
increases in resting vasodilatory capacity via repetitive exposure to increased pulsatile 
blood flow (Ray & Carrasco, 2000; Taylor et al., 2003). Chronic exposure to this larger 
isometric stimulus (due to larger muscle mass), may elicit greater post-training 
improvements in resting endothelial function while concomitantly ameliorating or 
improving post-exercise endothelial dysfunction, as higher intensity upper extremity 
isometric training can significantly reduce the formation of exercise-induced ROS (Peters 
et al., 2006). 
To add, acute isometric exercise bouts have been proven to significantly increase 
shear stress rate (a stimulus responsible for the metabolic cascade necessary for 
vasodilation and subsequent blood flow) from 25.2+/- 2.3 seconds"1 (baseline) to 41.9+/-
5.2 seconds-1(McGowan et al., 2006b). Therefore, repeated bouts of bilateral isometric 
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exercise (training) could produce a larger and potentially longer lasting metabolic effect 
of shear stress, allowing for a delayed reduction in blood flow during aerobic exercise in 
a population with PAD and DM, more specifically, T2D. It is also possible that the 
larger blood vessels of the lower extremities may require more time for metabolite 
accumulation preventing or minimizing metabolite-aided vasodilation thus increasing the 
reliance on endothelium-dependent vasodilation and fostering improvements in 
endothelial dysfunction. 
The increase in vasodilation and blood flow would allow individuals to exercise 
aerobically for longer and reap the benefits for their T2D and PAD treatment. Increased 
resting vasodilation would create a greater initial or pre-exercise blood flow potentially 
increasing the margin between sufficient and reduced blood flow during exercise. As 
reduced blood flow causes claudication, this would increase the time to claudication. 
Increased post-exercise blood flow could be an indicator of improvement in physiological 
processes responsible for defending against claudication. In this situation, isometric 
exercise training may act as a bridge to aerobic exercise. 
Pharmacological and Surgical Treatment Options for PAD 
There is no true pharmacological treatment method for PAD, however, the risk 
factors for PAD, hypertension and dyslipidemia, can be controlled or stabilized through 
the prescribed use of pharmaceutical drugs. Anti-platelet (e.g., acetylsalicylic acid), 
vasodilating (e.g., Cilostazol), cholesterol-reducing (e.g., Lipitor), and BP lowering 
medications (e.g. ACE inhibitors) are often prescribed to individuals with PAD to cease 
disease progression and aid in symptom remedy. (American Heart Association, 2009a) 
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Surgical treatments are recommended for individuals with extremely severe, 
debilitating, or aggressively progressing PAD. Angioplasty is a surgical procedure where 
a balloon is inflated in the artery and compresses the lesion against the arterial wall 
increasing the luminal space. A stent (wire mesh cylinder) can be inserted following 
angioplasty to help keep the artery open to the new luminal diameter created. If the PAD 
spans a large enough portion of the artery or completely impedes the artery's blood flow, 
then a bypass can be performed. A bypass consists of rerouting the blood flow around 
the blocked artery. A vein is taken from elsewhere in the body and used for this 
rerouting. An artificial artery (made from Gortex) can be used instead of a vein. 
(American Heart Association, 2009a) 
1.3 Summary of Background 
DM affects almost 200 million people worldwide and decreases age-expectancy 
and increases the risk of cardiovascular disease (World Health Organization, 2008; World 
Health Organization, 2009b; Grundy et al., 2009). Approximately 95% of the population 
with DM are classified under the T2D sub-category (Berg, 1986) and suffer not only 
from the disease, but from its complications, such as PAD (Canadian Diabetes 
Association, 2008). Although not specific to DM populations, the weight of evidence 
suggests that exercise as an intervention can decrease the symptoms of PAD (e.g., 
claudication) (Zwierska et al., 2005; Hiatt et al., 1990; Hiatt et al., 1994). However, the 
information available on the effects of isometric training on PAD and its symptoms in 
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DM is limited. Isometric training studies have been shown to promote an increase in 
resting vasodilation and post-exercise blood flow (McGowan et al., 2006a; McGowan et 
al., 2006b; Thompson et al. 2007; Lind & Williams, 1979). As claudication is caused by 
a reduction in blood flow (Gardner & Montgomery, 2008), and blood flow is calculated 
as the product of (nv )v, ('r' refers to the radius of the blood vessel, V refers to the 
velocity of the blood), increased resting vasodilation would create a greater pre-exercise 
blood flow potentially increasing the margin between sufficient and reduced blood flow 
during exercise, and increased post-exercise blood flow could be an indicator of 
physiological improvement processes responsible for defending against claudication. 
Taken together, the potential exists for bilateral lower extremity isometric training to be 
an effective intervention for claudication caused by PAD in T2D. 
At present, investigation into the effect of bilateral lower extremity isometric 
training on blood flow in individuals with T2D and PAD with debilitating intermittent 
claudication is limited. Individuals with T2D and intermittent claudication are often 
unable to participate in any aerobic exercise or participate to a health-beneficial extent 
due to low-intensity claudication onset. The effect of bilateral lower extremity isometric 
training on claudication is also limited and warrants further investigation. Bilateral 
isometric exercise training may act as a bridge to aerobic exercise. 
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1.4 Thesis Objectives 
The purpose of the proposed study is 1) to determine if isometric leg training 
increases the initial and absolute claudication distances, and 2) to determine if increased 
blood flow is a potential mechanism responsible for the observed improvements in 
claudication distances. 
1.5 Specific Hypotheses 
The primary hypothesis of this study is that in diabetic individuals with PAD 
bilateral lower extremity isometric training will increase initial and absolute claudication 
distances (ICD, ACD). A secondary hypothesis is that increased blood flow to the 
trained limbs is a potential mechanism responsible for the observed improvements in 
claudication distances. 
1.6 Clinical Relevance 
The work of this thesis will provide a foundation for and better understanding of 
the effects of bilateral lower extremity isometric training on PAD in persons with T2D. 
The results of this research may provide new interventions and protocols for individuals 
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suffering from PAD and claudication. In addition, the practice of bilateral lower 
extremity isometric training may also promote better T2D management, as this form of 
exercise may increase the locomotor ability necessary for the aerobic exercise programs 
that help control hyperglycemia. 
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CHAPTER 2: Lower Extremity Isometric Training and its Effect on 
Type 2 Diabetic Claudication 
MANUSCRIPT 
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2.1 Introduction 
Type 2 diabetes mellitus (T2D) affects over 180 million people worldwide (World 
Health Organization, 2008), of which 1.7 million are Canadian (Statistics Canada, 2010). 
These figures are only the reported cases and show a trend that displays a steadily 
increasing affected population (Statistics Canada, 2010). T2D is a disease characterized 
by elevated blood glucose (hyperglycemia) due to inadequate insulin action and 
decreased insulin sensitivity (Weir & Bonner-Weir, 2004) and is associated with 
numerous co-morbidities, a prominent one of which is peripheral arterial disease (PAD). 
PAD is a progressive disorder defined by structural changes in blood vessels and is 
associated with poor endothelial function (e.g., reduced nitric oxide (NO)-mediated or 
endothelial-dependent arterial vasodilation) and dyslipidemia (abnormal lipid profile) 
causing intermittent claudication (leg cramping) as a result of reduced blood flow during 
aerobic exercise (American Heart Association, 2008). Up to an estimated 54% of the 
T2D population have PAD (Faglia et al., 1998; Hirsch et al., 2001). 
Aerobic exercise training is a cornerstone therapy in the management of T2D 
(American College of Sports Medicine, 2010), and is associated with increased insulin 
sensitivity (Oguri, Adachi, Ohno, Oshima, & Kurabayahi, 2009; Winnick et al., 2008) 
and improved glucose regulation (Kennedy et al., 1999). PAD can also be successfully 
managed with aerobic exercise training (Treat-Jacobson, Bronas, & Leon, 2009), and is 
responsible for increased locomotive ability and reduced leg cramping in the PAD 
population (American Diabetes Association, 2003). Treat-Jacobson and colleagues 
(2009) found that 12 weeks of aerobic exercise training using arm ergometry, treadmill 
walking or both, increased maximal walking distance (absolute claudication distance; 
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ACD) by approximately 53%, 69% and 68%, respectively in a population of T2D with 
PAD population. Aerobic walking exercise programs (3 hours of walking per week, at a 
self-selected pace) lasting 12 have shown to increase maximal walking time by 
approximately 74% in a population of PAD patients with and without T2D (Hiatt, 
Wolfel, Meier, & Regensteiner, 1994). 
Although aerobic exercise is the universally accepted exercise-form of treatment 
and management in diabetic individuals with PAD, as these patients are often limited by 
leg cramping, this form of exercise can be excessively challenging and, in some cases, 
intolerable (American College of Sports Medicine, 2010). This often discourages 
individuals from seeking out or adhering to aerobic exercise training programs. 
A form of exercise that promotes prolonged increases in post-exercise blood flow 
is isometric exercise, which is relatively under-investigated, especially in clinical 
populations. For example, a single bout of isometric handgrip exercise increases blood 
flow to the working tissues post-exercise in healthy and clinical (e.g., hypertensive) 
populations using bilateral or unilateral, single and multiple contraction protocols at 
varying intensities (Lind & Williams, 1979; Thompson et al., 2007; McGowan et al., 
2006a), yet it is also associated with an acute attenuation in endothelium-dependent 
vasodilation in the latter populations (McGowan et al., 2006a). Chronic upper extremity 
isometric exercise training is associated with an increase in resting vasodilatory capacity 
(McGowan et al., 2006a), however, with respect to acute bout hemodynamics, neither the 
magnitude of the increase in post-exercise blood flow is augmented, nor is the transient 
reduction in endothelium-dependent vasodilation is ameliorated with training. The likely 
cause of reduced NO-mediated or endothelial-dependent arterial vasodilation is 
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peroxynitrite formation from a reaction between NO and reactive oxygen species (ROS) 
(Li & Fostermann, 2000), which are created during ischemic conditions (Alessio et al., 
2000) such as isometric exercise. This phenomenon of increased blood flow/decreased 
endothelial function, irrespective of training status, could be due to an accumulation of 
metabolites, such as adenosine (Costa & Biaggioni, 1998), that cause the dilation of 
blood vessels in order to decrease their local concentration (Herlihy, Bockman, Berne, & 
Rubio, 1976) thus not requiring endothelial-dependent vasodilation. 
To date, there are few published bilateral lower extremity isometric training 
studies and none on the effects on blood flow or endothelial function in T2D 
claudication. One study examined resting arterial blood pressure (BP) in healthy 
individuals performing 4, 2 minute contractions at 30% maximum voluntary contraction 
3 days per week for 8 weeks (Wiles, Coleman, & Swaine, 2009). It is possible that 
chronic exposure to a larger isometric stimulus (due to larger muscle mass), such as a 
bilateral lower extremity isometric training protocol, may elicit greater post-training 
improvements in resting endothelial function while concomitantly ameliorating or 
improving post-exercise endothelial dysfunction, as higher intensity upper extremity 
isometric training can significantly reduce the formation of exercise-induced ROS (Peters 
et al., 2006). To add, acute isometric exercise bouts have been proven to significantly 
increase shear stress (a stimulus responsible for the metabolic cascade necessary for 
vasodilation and subsequent blood flow) (McGowan et al., 2006b), therefore, repeated 
bouts of bilateral isometric exercise (training) could produce a larger and potentially 
longer lasting metabolic effect of shear stress, allowing for delayed onset of blood flow 
reduction during aerobic exercise in the T2D/PAD population. It is also possible that the 
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larger blood vessels of the lower extremities may require more time for metabolite 
accumulation preventing metabolite-aided vasodilation thus increasing the reliance on 
endothelium-dependent vasodilation and fostering improvements in endothelial 
dysfunction. 
The increase in vasodilation and blood flow would allow individuals to exercise 
aerobically for longer and reap the benefits for their T2D and PAD treatment. Increased 
resting vasodilation may create a greater initial or pre-exercise blood flow potentially 
increasing the margin between sufficient and reduced blood flow during exercise. As 
reduced blood flow causes claudication, this would increase the time to claudication. 
Increased post-exercise blood flow could be an indicator of improvement in physiological 
processes responsible for defending against claudication. 
At present, investigation into the effect of bilateral lower extremity isometric 
exercise training on vascular function, including blood flow, in individuals with T2D and 
PAD with debilitating intermittent claudication is limited. As previously mentioned, 
individuals with T2D and intermittent claudication are often unable to participate in 
aerobic exercise due to low-intensity claudication onset. In this situation, isometric 
exercise training may act as a bridge to aerobic exercise. 
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2.2 Purposes and Hypotheses 
The purpose of the current study was to test the primary hypothesis that in 
diabetic individuals with PAD, 8 weeks of bilateral lower extremity isometric training 
will increase initial and absolute claudication distances (ICD, ACD). A secondary 
purpose was to test the hypothesis that increased blood flow to the trained limbs is a 
potential mechanism responsible for the observed improvements in claudication 
distances. 
2.3 Methods 
2.3.1 Participants 
This study was cleared by the University of Windsor Research Ethics Board 
(REB#10-101) (see Appendix A), as well as the Windsor Regional Hospital Research 
Ethics Board (see Appendix B). Individuals with concurrent T2D and PAD (diagnosed 
by their primary care physician) aged 18 years and older, were recruited over an 11 
month period to participate in this study. Patients were excluded if they had a lower 
extremity amputation, walked with an assisting device (walker, cane, etc.), had heart 
failure and/or a cardiovascular event (cardiac arrest, stroke, transient ischemic attack) or 
hospitalization in the 12 weeks prior to the study (American College of 
Cardiology/American Heart Association, 2004). Individuals were recruited from the 
University of Windsor's general population, local physician offices, diabetes community 
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programs, cardiovascular and chronic disease management programs, and the community 
at large. Participants were recruited by means of a poster campaign (see Appendix C) 
across the previously stated locations and via personal interaction. 
Participant characteristics are presented in Tables 2.1-2.4. Forty individuals were 
recruited to participate in the study, but rejected their participation due to time 
constraints. Six individuals attended the initial visit, however, 1 individual was excluded 
from the study due to a vascular surgery procedure and another individual dropped out 
before the testing day. Ultimately, four individuals with T2D and PAD participated in 
this study. All participants were Caucasian males, age 65.3±4.6 years (Mean ± SD) and 
were regular exercisers (1.8±0.9 hours per day, 4.8±2.1 days per week). At the time of 
the study, each participant was on standard pharmacotherapy for T2D and PAD, 
however, no one was being treated for claudication pain. Only two participants 
completed the 8-week intervention; due to circumstances beyond control of the 
investigators, the remaining 2 participants completed a 7- and 6-week intervention, 
respectively. 
2.3.2 Study Design 
This study was designed as a randomized, controlled trial; however, due to poor 
recruitment, it was collapsed into a within-study design, using an intent-to-treat approach. 
After inquiring about the study, participants were required to meet with the study 
investigators at the Physical Activity & Cardiovascular Research (PACR) Lab (Room 
#240, Human Kinetics Building, University of Windsor, ON, Canada) for an 
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informational meeting. During the meeting, the participants signed a letter of information 
(see Appendix D), signed an informed letter of consent (see Appendix E), completed a 
medical questionnaire (see Appendix F) and were given the physical activity readiness 
medical examination (PARmed-X) (see Appendix G) to be signed by their primary care 
physician. Following the establishment of eligibility via the medical questionnaire and 
PARmed-X, participants returned to the PACR Lab for familiarization of all testing and 
training procedures and completed a personal history questionnaire (see Appendix H) and 
signed a medical history release form (see Appendix I). 
Testing Protocol 
Testing took place over 1 day (approximately 1 hour), prior to (week 0) and 
following (week 7 or 8 or 9) the intervention. To minimize the influence of external 
factors on the tested measures, participants were asked to refrain from the consumption of 
alcohol and caffeine for 12 hours prior (McGowan et al., 2006a) and smoking for 30 
minutes prior (Primatesta et al., 2001). On the testing days, participants were required to 
wear a short-sleeved t-shirt and shorts to ensure accuracy of measurements. 
All testing took place in the PACR Lab. First, the participants rested in the supine 
position for 10 minutes (Weatherley et al., 2006), after which arterial BP (Dinamap 
ProCare 100, Critikon, Tampa, FL, USA; see Appendix J) was acquired using automated 
arterial oscillometry in the following order: right brachial BP, left brachial BP, right 
posterior tibial BP, left posterior tibial BP, right dorsalis pedis BP and left dorsalis pedis 
BP. BP was taken once more in the same order to give two series of BP measurements. 
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These measurements were used in the analysis of individual leg ankle-brachial index 
(ABI; described below), a measure of PAD severity and disease progression. 
Next, participants underwent a pre-walking popliteal artery duplex scan using B-
mode and Doppler-mode ultrasound (Vivid i, GE Health, Pittsburgh, Pennsylvania, USA; 
see Appendix K) (frequency=8.0/4.4 MHz; depth=4.0/5.0 cm; angle of isonation=60°) 
with electrocardiogram (ECG) gating. Participants were required to lie in the prone 
position with the backs of their knees accessible to the investigator. The diameter of each 
popliteal artery and the concomitant blood velocities were collected continuously for 1 
minute (Parker et al., 2006). 
Once the necessary popliteal images were acquired, participants performed a 
graded-exercise treadmill test as per the Gardner protocol (see Appendix L). In brief, 
participants stated when they first felt pain/cramping in their legs (initial claudication 
distance; ICD) and when the pain/cramping became too intense to withstand the test any 
further (absolute claudication distance; ACD). Immediately after the completion of the 
treadmill test, all participants underwent a post-walking popliteal artery duplex scan 
following the same protocol as previously described. 
Training Protocol 
Participants trained 3 times per week, for a total of 6, 7 or 8 weeks. Each training 
session took place in the PACR Lab under the direct supervision of an exercise trainer. 
Participants were first asked if there had been any change in medication, nutrition or 
physical activity routine (McGowan, et al. 2007) to ensure that these variables remained 
unchanged throughout the study. Next, participants had their blood glucose levels 
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analyzed using a commercially available blood glucose monitoring system (Abbott 
Laboratories Freestyle Freedom Lite; see Appendix M) where blood was applied to a the 
system's testing strip after being lanced with a spring-loaded lancet (Accuchek SoftClix; 
see Appendix N). Individuals with a blood glucose reading of less than 4 mM were to be 
given a carbohydrate snack to prevent possible adverse effects of hypoglycemia 
(Canadian Diabetes Association, 2004). 
After blood glucose analysis, resting BP and ABI (following the same protocol as 
the testing days; data not used for analysis) were acquired after 10 minutes of supine rest. 
After the establishment of a safe BP, brachial systolic BP of >200 mmHg or diastolic BP 
of >110 mmHg (American College of Sports Medicine, 2010), participants performed 
bilateral lower extremity isometric exercise using the Lower Leg Isometric Training 
Apparatus (LoLITA; see Appendix O). Specifically, 4 sets of bi-legged, 2-minute 
isometric lower extremity contractions at 30% maximal voluntary contraction (MVC; 
determined at the onset of each training session via the Sustain Optimal Load Exercise 
Software (SOLES) program contained within LoLITA) were performed, each separated 
by 2-minute rest intervals (Wiles et al., 2009). Throughout the isometric exercise, BP was 
monitored every 2 minutes, as a safety precaution. Immediately post-exercise, blood 
glucose (as a precaution for hypoglycemia; same action plan as for the pre-training blood 
glucose analysis), BP and ABI were assessed. 
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Data Analysis 
Claudication Distances 
As previously mentioned, ICD and ACD were determined using the Gardner 
Protocol (see Appendix L). This standardized test is used clinically across all age groups 
and disease states and has a within-subject variation of 15-25% for ICD and 12-13% for 
ACD (Hiatt, Nawaz, Regensteiner, & Hossack, 1998). Prior to the commencement of the 
graded-exercise treadmill test, participants were asked to only speak to the investigator at 
the time of the initial onset of leg pain/cramping (ICD) and when they felt they could no 
longer withstand the test (ACD). To control for the influence of motivation on time to 
claudication, the investigator only spoke to notify participants of the incline increase 
during the test and to acknowledge the claudication distances. Furthermore, participants 
were blinded to their pre-intervention results following training. 
Pre-Exercise and Post-Exercise Blood Flow 
Blood flow was calculated separately for each artery using the product of (7ir2)v 
where 'r' refers to the radius of the blood vessel and V refers to the velocity of the blood 
(McGowan et al., 2006b). The radius of each artery was determined from the artery's 
diameter. Specifically, three diameters (leading-edge to leading-edge) of the artery were 
obtained at each R peak of the QRS-complex of the electrocardiogram for the entire 
minute (Parker, Ridout & Proctor, 2006). The three diameters of each R peak were 
averaged, and then that average was averaged with the other R peak averages (Parker, 
Ridout & Proctor, 2006), then divided by two to give the artery's radius. Average mean 
blood velocity was determined using the average of all the timed-average means of beat-
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to-beat mean blood velocity of that artery (Vivid i, GE Health, Pittsburgh, Pennsylvania, 
USA). Diameter and velocity raw data is presented in Tables 3.1 and 3.2. 
To ensure measurement accuracy the same investigator performed all testing and 
analysis procedures. To further enhance accuracy, the investigator used anatomic 
landmarks and compared each participant's subsequent arterial duplex images to his 
initial arterial duplex image. 
Resting ABI 
The resting ankle-brachial index (ABI) was determined with a calculation using 
the various BP measurements obtained during the testing days. The highest brachial BPs 
from each series and the highest ankle BP (dorsalis pedis or posterior tibial) of each leg 
from the same series were used to calculate the ankle-brachial index (quotient of the 
ankle arterial systolic BP and brachial arterial systolic BP) (Benchimol et al., 2004; 
Beckman, Higgins, & Gerhard-Herman, 2006). The average ABI of the two series for 
each leg was used. Resting ABI data is presented in Tables 3.3. 
Blood Glucose 
Blood glucose measurements were obtained and analyzed using a commercially 
available blood glucose monitoring system (Abbott Laboratories Freestyle Freedom Lite; 
see Appendix M) where blood was applied to a the system's testing strip after being 
lanced from the participants' thumbs, index or middle fingers with a spring-loaded lancet. 
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Statistical Analysis 
Statistical significance was set at P<0.05. A Sign Test, a non-parametric test 
which is designed to test results against predicted hypotheses, was performed on 
claudication distance and blood flow data. A repeated measures analysis of variance, a 
parametric test which measures the effect of an intervention on the same characteristic 
under different conditions, was performed to assess the effects of training on the change 
in blood glucose concentrations pre- and post-exercise. All tests were performed using 
Predictive Analytics Software version 18 (PASW 18). 
2.4 Results 
ICD/ACD 
Following bilateral lower extremity isometric training, ICD and ACD improved 
by an average of 116.3±26.3% (pre: 165.9 ± 107.9 m to post: 338.0 ± 171.9 m) and 
47.5±34.1% (pre: 390.3 ± 163.8 m to post: 559.3 ± 208.8 m), respectively. First, the 
claudication distance data was statistically analyzed as two separate data sets in two 
separate Sign Tests: 1)ICD (Z=1.5; p=.125) and, 2) ACD (Z=1.5; p=.125). Both data sets 
displayed no statistical significance. As the Sign Test is a non-parametric test which does 
not require data normality or homogeneity, and as ICD and ACD are related because they 
both measure claudication distance, the two data sets were pooled into one to increase the 
power of the data. Statistically significant increases were observed in the pooled 
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claudication distance data (Z=2.475; p=.008). Guidelines for clinically significant 
improvements in claudication distance(s) do not exist, therefore it is unclear if the 
improvements classify as clinically significant as well as statistically. See Table 4.1. 
Blood Flow 
The effect of bilateral lower extremity isometric training on blood flow was 
analyzed first by assessing each of the four separate data sets in four separate Sign Tests: 
1) Pre-exercise right leg blood flow (Z=0; p=1.0), 2) Pre-exercise left leg blood flow 
(Z=.5; p=.625), 3) Post-exercise right leg blood flow (Z=.5;p=.625), and 4) Post-exercise 
left leg blood flow (Z=1.5;p=.125). As no statistical significance was detected with any 
analyses, the four data sets were pooled into one. However, no statistically significant 
changes in blood flow were observed (Z=.516, p=.607). See Tables 4.2 and 4.3. 
ABI 
Following training, there were neither statistically significant (all p>0.05) nor 
clinically relevant changes in ABI (see Table 3.3). With respect to the latter, clinically, a 
decrease in ABI of 0.15 indicates PAD progression (McLafferty, Moneta, Taylor, & 
Porter, 1997; Criqui, Ninomiya, Wingard, Ji & Fronek, 2008), while an increase in ABI 
of 0.15 is indicative of disease improvement (as seen post-surgical intervention) 
(Eberhardt, 2003). Collectively, these data suggest there were no changes in ABI and 
subsequently no disease progression. 
Blood Glucose 
The change in blood glucose concentrations from pre- to post-exercise session 
remained unchanged with training, F(3, 54)= 1.39, p=0.255. See Table 3.4. 
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2.5 Discussion 
T2D is a highly prevalent chronic disease worldwide, and PAD is a common 
comorbidity associated with the disease. PAD causes severe claudication pain in the 
lower legs during activities as simple as walking, due to insufficient blood flow, and thus 
negatively influences exercise capacity. This is concerning, as aerobic exercise is a key 
form of treatment and management in T2D. 
Isometric exercise is a novel form of exercise that is non-claudication promoting, 
improves local resting vasodilatory function in clinical populations and increases local 
post-exercise blood flow in healthy and clinical populations. Considering this evidence, 
isometric exercise has the potential to be a viable intervention to increase ICD and ACD 
by increasing blood flow to the trained tissues, subsequent to or independent of increased 
local vasodilatory function. Furthermore, isometric exercise performed using a large 
muscle mass may encourage greater improvements in those variables. 
In support of the primary hypothesis, bilateral lower extremity isometric exercise 
training performed at 30% MVC for 4, 2-minute contractions increased ICD and ACD. 
The mechanism(s) responsible for this increase remain unclear, and as popliteal artery 
blood flow remained unchanged in the current study, it is an unlikely mechanism. One 
possible mechanism may be an increase in collateral blood vessel circuits (Murrant, 
2008). Animal studies have shown that regular physical activity can increase the 
conductance of these collateral vessels (Murrant, 2008), providing blood flow to areas 
affected by PAD, and delaying claudication. 
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Another possible and more probable mechanism for increased claudication 
distance is ischemic adaptation. Individuals with PAD have low-functioning and 
depleted amounts of vascular smooth muscle cells (VSMCs) (Bennett, 2006; Bennett, 
Macdonald, Chan, Boyle, & Weissberg, 1998; Ross, Wight, Strandess, & Thiele, 1984), 
leading to attenuated NO metabolism and impaired vasodilation. Sustained isometric 
contractions can temporarily attenuate blood flow due to vascular constriction or 
collapse, and exercises which cause ischemic conditions during their performance 
increase NO availability (Kimura et al., 2007). Therefore, the more readily available NO 
could travel to the mitochondrial cells of skeletal muscles where it causes attenuation in 
oxygen consumption (Cooper & Brown, 2008) promoting greater oxygen availability for 
muscle contraction-relaxation which delays muscle cramping. 
As previously mentioned, popliteal artery blood flow remained unchanged with 
training. It is possible that the participants had very severe endothelial damage that could 
not be improved in the short-term training period. The progression of PAD (measured by 
changes in ABI) correlates with increasing endothelial dysfunction and decreased 
vasodilatory ability (Brevetti et al., 2003), however, individuals with PAD who have T2D 
are very prone to arterial calcification (Chen & Moe, 2003) causing arteries to become 
permanently stiff and rigid. Stiffening of the arteries causes artefactually elevated ABIs 
(Bernstein & Fronek, 1982) masking the true severity of PAD and the extent of 
endothelial dysfunction. Also, calcification alone causes arteries to have dysfunctional 
endothelium and poor distensibility (Giachelli, 2004) and therefore, low vasodilatory 
ability. However, this study did not measure endothelial function directly, therefore, this 
theory cannot be fully supported nor ruled out. Although medication and diet was closely 
77 
monitored throughout the study, specific medication and nutritional data were not 
acquired, and thus one or more pharmacological and/or nutritional factor(s) may have 
influenced the ability of the endothelium to change. 
Another reason for the lack of blood flow improvement could be the location of 
and/or the time course of the blood flow measurement. First, this study assessed blood 
flow using only the popliteal artery, which is a conduit and not a collateral vessel. As 
previously mentioned, collateral blood vessel circuits increase their conductance with 
exercise and may be responsible for increased blood flow to areas below atherosclerotic 
disease and arterial occlusions (Murrant, 2008). Second, blood flow during exercise was 
not examined, therefore there is no data to determine or interpret hemodynamics during 
exercise and at the time of claudication. 
2.6 Limitations 
This study was limited due to the sample size which affected the power of the 
study. The study was originally designed as a randomized, controlled trial, but had to be 
collapsed to a within-subject design. Without a control group it was difficult to assess the 
magnitude of the isometric training intervention. Difficulty with participant recruitment 
can be attributed to the training protocol as many of the prospects declined their 
participation because of the amount of on-site time required (approximately 1 hour, 3 
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times per week for 8 weeks). Some potential participants were living in elderly care 
facilities with no mode of regular transportation to the facility. 
This study employed an intent-to-treat approach. The primary goal of the study 
was to increase both ICD and ACD in individuals with T2D and PAD, and although 
performed with a small sample size and differing intervention lengths, the study did show 
positive and statistically significant results with respect to claudication distances. These 
results can be confidently defended because the tool used to assess claudication distance, 
the Gardner Protocol, is widely used in both clinical and research domains, and has low 
within-subject variability, even though participant self-motivation may skew data. This 
study's results were also obtained from male participants with similar between-subject 
characteristics such as age, ethnicity, physical activity level and prescribed medication. 
To further add to the strength of this study's findings, the participants had differing 
between-subject views with respect to their personal feelings of the study outcome, 
ranging from feelings of disappointment (even with improved ICD/ACD) to success (as 
one participant developed a continuing at-home program). 
Assessment of two more variables, blood flow during exercise and endothelial 
function, would have provided us additional data and possibly more insight into the 
mechanisms causing increased ICD and ACD in this population. Blood flow during 
exercise could not be measured as it is difficult to perform duplex ultrasounds and 
acquire accurate images on participants in motion, particularly on a treadmill. Regarding 
endothelial function, current non-invasive methods of measurement use prolonged 
suprasystolic cuff occlusion of the limbs (Parker, Ridout, & Proctor, 2006). Although 
this method is accurate, it is not reasonable for individuals with T2D and PAD who are 
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likely to suffer from neuropathy (Canadian Diabetes Association, 2008), resting leg pain 
(Beard, 2000) and venous insufficiency (Donnelly, Emslie-Smith, Gardner, & Morris, 
2000) which can make the procedure painful and unbearable. Also, prolonged occlusion 
of the venous system and/or the use of an improperly fitted cuff can cause venous trauma 
and initiate inflammation and phlebitis (blood clot formation) (National Institutes of 
Health, 2011b), which in some circumstances can lead to a pulmonary embolism 
(National Institutes of Health, 2011a). 
Another limitation of the study was that the dosage of and time of injection of 
insulin were not monitored. Insulin has vasoactive effects and can act as either a 
vasodilator or vasoconstrictor (Eringa, Stehouwer, Merlijn, Westerhof, & Sipkema, 2002; 
Verma, Yao, Stewart, Dumont, Anderson et al., 2001) which can cause it to interfere with 
arterial diameters and subsequent measurement and analysis. 
2.7 Conclusion 
Bilateral lower extremity isometric exercise training can increase both ICD and 
ACD in individuals with concurrent T2D and PAD, however, increased local blood flow 
cannot be identified as the mechanism responsible for the improvement. Further research 
is needed in order to replicate these preliminary findings, and to determine the processes 
that cause increases in ICD and ACD following bilateral lower extremity isometric 
exercise training. Future studies involving bilateral lower extremity isometric exercise 
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and ICD/ACD should examine the combined blood flow of all the infrageniculate arteries 
(rather than isolating one) and mitochondrial respiration. 
2.8 Clinical Relevance 
The findings of the present study provide a foundation for future large-scale 
studies designed to better understand the effects of bilateral lower extremity isometric 
training on PAD and its complications in persons with T2D. Although still in the early 
stages of investigation, the results of this research will serve as a basis for future studies 
designed to investigate blood flow and isometric exercise, potentially providing an 
alternative treatment option for individuals suffering from PAD and claudication. The 
practice of bilateral lower extremity isometric training may also promote better T2D 
management, as this form of exercise may increase the locomotive ability necessary for 
the aerobic exercise programs that help control hyperglycemia. 
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Table 1. 
Summary of the Differences Between Type 1, Type 2 and Gestational Diabetes 
Characteristics Type 1 Type 2 Gestational 
Alternate Name(s) Juvenile-onset, 
Insulin-dependent 
Adult-onset, 
Non-insulin dependent 
(none) 
Prevalence 
Time of Onset 
Pathology 
5-10% of diabetics 
Before age 20 
The body does not 
produce insulin 
90-95% of diabetics 
After age 40 
The body is resistant to 
insulin 
4% of 
pregnant 
women 
During 
pregnancy 
The body is 
resistant to 
insulin 
Note. The information is from "Diabetics Guide to Health and Fitness", by K. Berg, 
1986, Champaign, IL, Life Enhancement Publications; and "Gestational Diabetes: 
Preventing Complications in Pregnancy", by the Canadian Diabetes Association, 2009. 
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Table 2.1 
Participant Characteristics: Age, Sex and Race 
Participant 
1 
2 
3 
4 
Age (years) 
70 
60 
63 
68 
Sex 
male 
male 
male 
male 
Race 
Caucasian 
Caucasian 
Caucasian 
Caucasian 
Table 2.2 
Participant Characteristics: Peripheral Arterial Disease-Related 
Participant 
1 
2 
3 
4 
Age 
diagnosed 
unknown 
58 
47 
unknown 
Pain 
medication 
No 
No 
No 
No 
Hypertension 
medication 
Yes 
Yes 
Yes 
Yes 
Hyperlipidemia 
medication 
Yes 
Yes 
Yes 
Yes 
Anti-
coagulation 
medication 
Yes 
Yes 
Yes 
Yes 
Table 2.3 
Participant Characteristics: Type 2 Diabetes-Related 
Participant 
1 
2 
3 
4 
Age diagnosed 
39 
54 
47 
52 
Oral 
medications 
Yes 
Yes 
Yes 
Yes 
Insulin 
began at age 39; ended at age 68 
Never 
began at age 60 and continuing 
began at age 59 and continuing 
92 
Table 2.4 
Participant Characteristics: Physical Activity History 
Participant High school sports Post-high school 
(age 18-50 years) 
Golden years (age 
50+ years) 
Football team, 
basketball team, 
wrestling team 
Dancing (ld/wk) Dancing (ld/wk) 
1 hr walk (2d/wk) 
1 hr water aerobics 
(2d/wk) 
None Pick-up hockey 
(ld/wk) 
1 hr walk (2d/wk) 
Football team Recreational baseball 
(1 d/wk) 
1 hr water aerobics 
(5d/wk) 
None Physically demanding 
jobs (5d/wk) 
Physically demanding 
jobs 
(5d/wk until age 63) 
1 hr walk (3d/wk) 
2 hr walk (4d/wk) 
Note. Hour (hr), day (d), week (wk) 
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Table 3.1 
Raw Data: Popliteal Artery Diameters (cm) 
Pre-Intervention 
Pre-Exercise 
Participant Right Left 
Post-Exercise 
Right Left 
1 0.80 0.81 0.79 0.80 
2 0.81 0.79 1.22 0.87 
3 0.56 0.55 0.5 0.54 
4 0.73 0.74 0.7 0.78 
Post-Intervention 
Pre-Exercise 
Right Left 
Post-Exercise 
Right Left 
0.79 0.79 0.83 0.83 
0.80 0.79 0.78 0.77 
0.58 0.59 0.59 0.59 
0.71 0.74 0.70 0.76 
Table 3.2 
Raw Data: Popliteal Artery Timed-Average Mean Velocity (cm/sec) 
Pre-Intervention 
Pre-Exercise 
Participant Right Left 
Post-Exercise 
Right Left 
1 1.10 2.66 3.22 3.22 
2 4.65 6.54 34.90 16.63 
3 10.24 14.86 25.37 44.50 
4 6.32 5.12 8.06 5.97 
Post-Intervention 
Pre-Exercise 
Right Left 
Post-Exercise 
Right Left 
1.09 1.57 3.93 2.20 
6.81 4.47 10.38 12.71 
19.57 15.43 33.48 23.34 
6.28 3.85 3.74 6.01 
Table 3.3 
Raw Data: Resting Ankle-Brachial Index 
Pre-Intervention 
Participant Right Leg Left Leg 
1 1.10 1.13 
2 0.83 1.08 
3 
4 0.78 0.77 
Post-Intervention 
Right Leg Left Leg 
1.24 1.23 
0.81 1.00 
0.67 0.73 
Note. Ankle-brachial indices could not be determined for Participant #3 due to 'error display' on 
oscillometer, and Participants #1 and 2 may have elevated ankle-brachial indices due to arterial 
calcification. 
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Table 3.4 
Raw Data: Pre & Post-Exercise Session Blood Glucose Measurements (mM) 
Session 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Participant #1 
Pre 
7.7 
10.5 
7.7 
5.9 
5.2 
9.8 
11.3 
8.6 
6.4 
10.2 
7.8 
12.6 
6.1 
7.1 
10.2 
12.0 
12.0 
8.8 
7.5 
11.9 
Post 
6.4 
11.6 
6.9 
4.7 
4.5 
9.8 
10.1 
8.1 
4.9 
8.0 
7.8 
15.6 
5.9 
5.4 
9.5 
9.1 
15.0 
11.4 
8.6 
10.3 
Participant #2 
Pre 
11.1 
13.4 
12.4 
11.0 
9.7 
17.1 
17.8 
16.9 
12.7 
18.1 
14.1 
13.1 
12.8 
10.9 
12.5 
11.1 
-
-
-
-
Post 
16.9 
13.0 
16.2 
9.8 
10.8 
13.5 
18.6 
13.4 
12.0 
17.8 
15.5 
12.0 
10.9 
10.9 
9.3 
11.9 
-
-
-
-
Participant #3 
Pre 
8.2 
6.0 
6.7 
6.8 
6.0 
8.3 
7.1 
10.8 
8.1 
11.1 
5.7 
4.4 
6.1 
5.5 
8.8 
10.1 
8.2 
6.5 
6.6 
5.8 
Post 
8.9 
5.7 
6.7 
7.8 
6.2 
8.3 
7.2 
7.9 
6.1 
11.4 
5.9 
4.4 
6.8 
5.0 
8.2 
11.3 
13.8 
5.8 
6.8 
5.2 
Participant #4 
Pre 
11.8 
6.2 
6.9 
8.9 
9.0 
7.9 
12.1 
8.2 
6.6 
9.9 
7.3 
6.3 
9.1 
8.6 
9.2 
10.7 
12.1 
7.0 
8.1 
-
Post 
10.9 
4.9 
8.2 
7.5 
1.1 
6.1 
10.3 
7.1 
6.9 
9.7 
5.7 
5.7 
8.5 
9.1 
10.6 
10.4 
12.3 
6.9 
7.3 
-
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Table 4.1 
Results Table: Initial Claudication Distance (ICD)/Absolute Claudication Distance 
(ACD) (mi) 
Pre- Pre-
Intervention Intervention 
Participant ICD ACD 
1 0.07 0.18 
2 0.20 0.39 
3 0.09 0.23 
4 0.05 0.17 
Post- Post-
Intervention Intervention 
ICD ACD 
0.17 0.35 
0.36 0.53 
0.20 0.26 
0.11 0.25 
Table 4.2 
Results Table: Pre-Exercise Blood Flow (ml/sec) 
Pre- Pre-
Intervention Intervention 
Participant Right Leg Left Leg 
1 0.55 1.37 
2 2.46 3.29 
3 2.52 3.66 
4 2.72 2.20 
Post- Post-
Intervention Intervention 
Right Leg Left Leg 
0.55 0.79 
3.42 2.14 
5.17 4.08 
2.56 1.65 
Table 4.3 
Results Table: Post-Exercise Blood Flow (ml/sec) 
Pre- Pre-
Intervention Intervention 
Participant Right Leg Left Leg 
1 1.58 1.62 
2 4.08 10.11 
3 5.81 10.19 
4 3.85 2.85 
Post- Post-
Intervention Intervention 
Right Leg Left Leg 
2.18 1.16 
4.96 6.07 
8.85 6.17 
1.44 2.73 
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Figures 
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—» Normal Hood glucose 
I 
Eating 
I 
Elevated blood gheose 
I 
Sensed by pancreatic cells 
i 
Pamcresj secrete insulin 
I 
Increased ^ucese uptake by cells 
Figure 1. The Negative Feedback System of Contal for Blood Glucose. The blood ghicose 
ceocentratioB is elevated by eating and this elevation is sensed by pancreatic eels which secrete 
insulin in response to the elevation. The secreted insulin inftoenees inoessed glucose uptake by 
cells and, in mm. reduces and retams the blood glucose concentration to monad. 
Nole.TbE mianwHaa is fojm "Physiology of Stress", by M. Asenta, i9Z5r New Yoik, NY, H s m Sciences Press. 
98 
g^Hcose-fr-ph&spbate 
1 
fnictose-4-phosphate 
fructose-1,6-diphosphate 
eddaiase ^^^^^*****+^^ aidolsse 
dihydroxyacetoiie phosphate * ^ ^ ^ ^ glyteraldebyde-3-phQsphate 
isameraze* \ s^ceralds^ds-i-pmsphale 
\ * *The enzyme isomerase V defydrogmaze converts dahyekHxyscetoaa , _ , , , , 
pkjspfaafe isto &e secoa! ! 3-AphosphogIycerate 
(asa Sxst osujig tae COM tanned 
b r fiu£ta5e-I,6-dipliospkate 
aiid aldose). Bsft molecules 
of gi>c<Hal!fcJwie-3 -phosphate 
trawl tbic^i^i the pathway 
separately', hi otfasx woids, tb& 
steps ftom glyceraidekyde-3-
pl&O l^tliate to pyTERTSfee OCCS^  
twice per glueose-6-
pfcosapbatg molecule 
Figum 2 Glycolysis LB the Sacroplasm of tbe Beta Cell The figure depicts the pathway by 
which pyruvate is cieated from gincose-6-phospliate, and the enzymes (in italics) acting on each 
new molecule m the pathway. Also shown is the energy compound, adenosine triphosphate and 
when it is produced (from adenosine diphosphate) or Bsed (broken down to adenosine 
diphosphate). 
Nine. H e infmmsitism n fesus "Exercise Fbyaatogy. Ttosif SEd AppfcirtiGii to fitness and Pertammce", by S. 
Powers & E Bowley, 2®®§, New York, KY. McGnw-Hffl. 
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fiimerate 
FADBJ 
FAD n 
succinyl dsfy<ifc@gmiiss alpha 
citrate 
isocitrafe 
11 NAD 
« — J J • NADH-^ H 
alpha ketogfatarate 
are 11— NAD 
j | i > NADH-H 
succinate - ^ siKcmyl coenzyme A 
I 
ADP 
ZUCCBQTI coenzyme A symthsta&e 
Figure: 
which p 
t i. The Kreb' s Cycle m a Mkocomdrion of the Cell. The fipEre depicts the pathway by 
t yruvate is converted into different molecules allowing for the production of the energy 
caDapoond adenosine triphosphate (ATP) and reducing equivalents Bkotinaaaide adenine 
diimcleotide with 2 hydrogen ions (KADH+H) and flavin adenine dinudeotide with 2 hydrogen 
ions (FADf&) from the compotmis adenosine diphosphate (ADP), nkotinamide adenine 
dimicleotide (NAD) and flavin adenine dimucteotide ff AD) respectively. The ie&iciiig 
equivalents will travel to the electron transport chain to produce more ATP. Also shown are the 
enzymes (in italics) involved in the reactions. 
NMe. Tise iufiKmnum is fan ""Exercise Physiology: Ttaijy ani AgpbuiHai to 1 
i & E. Howtay, 2009, Ksw York, NY, McGraw-HHL 
r'.byS. 
100 
CJtGSQl 
outer membrane 
H+ H+ H-r H+ H- H- H- H- P ADP 
H- H+ . H~ H+ H+ H+ 
ATP 5 
H- H+ ^ ATP 
NAD H- H+ 2e-
t t t t 
inner compartment 
FAD H+ H+ 2e-
t t t t 
NADH+H 
cyiockrame oxidise 
2H+ - %02 *-H3G 
cyt/Kkmrneb-cl 
FADHi 
Figure 4. The Eiecsroa Transport Chain ia a Mitochondrion. The figure depicts the breakdown 
of the reducing equivalents nicotinamide adenine dnmcfeonde and 2 hydrogen JOBS (NADH-i-H) 
m& flavm adenine dinucleotide and 2 hydrogen ions (FADH;) by their respective enzymes (in 
italics). Also illustrated are electrons (2e-) traveling through the transport chain providing the 
energy to pinup hydrogen ion? (H+) into the outer compartment of the mitochondrion. The H- is 
brought back into the iaaer compartment using adenosine triphosphate (ATP) synthase whose 
action is coupled with the actions of the carrier proteins which transport phosphate ions (P) and 
adenosine diphosphate molecules (ADP). The enzyme cytochrome oxidase catalyzes the 
reaction of water (HzQ) production. 
:".bys. The infonrntism is torn "Exera.se PfaysioUsgy: Theory m& ApplicaHon to 
& E. Htnriey, 2BEB, New York, NY, McGraw-IWl 
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glucose potassium calcium 
Kreb's cycle 
\ 
ATP 
electron transport chain 
endoplasmic reticulum 
containing t 
caloom 
+ 
m^ilm 
iiitiacellalar space 
• cellular membrane 
eartraeeJMar space 
Figum J.Beta Cell Glucose Uptake and Insulin Release. The figure depicts glucose entry into the 
beta cell {via glucose transporter 2), and conversion into adenosine triphosphate (ATP) which 
mhibits the A IP-sensitive potassium (Kr) channel, an action that causes cell membrane 
depolarisrtio& and the opening of fc; voltage-gated calcium channel allowing calcium infinx. 
Calcium activates the enzyme phospholipase C which acts on phosphotidy3iiuKitol-4,5-
biphosphate {PIP;) to cleave it into inositol- 1,4,5-tripbospste (IPs) and diacylglycerol IPj, 
increase the release of calcium from the endoplasmic reticulam and this influences the process of 
insulin exocytosis -tram the cell and into the extracellular space. 
Norn. Has o t e a i x is fern '-Gfacose m a. Kfigokmr m GtaKS TxaaspoH ABBMBJ and Gtawe-Hrsnsporlei 
mHNA m Hxmsm Beta-Cell Lines", fev K. laagato. K. Yssmb. G. Tosot, Y. Gkamsto, H. Yam, Y. 
1992, Dobete, 41,592-597; ami "VsskiLge Koase MeasHremeas am»s &e PaaoBstk Befit-Gell 1 " 
CdriiaBOiai^CtascterisSKs'", by I. Attrato, C. Drawn. G. Edfflestane. ft E. Saps, 1981. 
Physfflkgy, 314.1*5-212. 
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tyrosine tanase (auctrre) tyrosine kinase (active) 
insulin receptor substrate proteins (aaactrre) insslitt receptor substrate proteins (actree) 
r -
insulin receptor substrate proteins-PB kinase complex 
protein kinase B (xtm) protein kinase B (inactive) 
^ 
GLUT4 
G1UT4 tmtstocstxsra to cell I 
Figure 6. Bisnlin-Stimulsted GLUT4 Translocation in a Muscle Cell. When msalin bands to the 
insulin receptor on the muscle cell it activates tyrosine kinase wMch activates insulin receptor 
substrate proteins. The insulin receptor substrate proteins bind to a id subsequently activate 
phosphotidylinositol-S kinase and this actios activates protein kinase B. Protein kinase B causes 
the protein AS16CS to dissociate from the glucose transporter protein 4 (GLUT4). When bound to 
GLUT4T AS1GG inMbits GLUT4 movements. Once AS160 is dissociated from GLDT4. GLUT4 
translocation is able to occur. 
JVtafelMsi 
Uptakes. 
774-785. 
is fesm "Mechanisms of iSgh-C3aaK«.&i£ijlii-MsdiaSBd 
TraiBport of Akt Amraam". bv K. Rotsiasoa & M. Base, 2fflJS. 
& Metabolism, 294, S7S-SS1; smd "Models for Segulafioa by 
Yeast", by G. Hanite. 2002. Nsstme Reww 
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gliKose 
idiptosptoffl 
extracellular space 
— cell] 
ghcose-6-phospihate 
intracellular space 
hezotnasc {skeletal} 
ghicose-1 -phosphate 
3 psmphosphawlaw 
undine diphosphate Euicose • 
uridine diphosphate 
glycogen 
glycogen 
Figiire 7. Glycogenesis in Skeletal Muscle ind liver Celk. Glacose enters the ee l and is acted 
on by the enzyme (in italics) hexokinase (in the skdetal muscle cell) or ghicokmase (in the liver 
cell) which uses energy from adenosine triphosphate to produce giucose-fi-phosphase. Glucose-
s-phosphate is converted into glucose-l-phosphate by mntase. Pyrophosphorylase catalyzes the 
reaction to produce uridine diphosphate from glncose-l -phosphate. Glycogen is then produced 
from uridine diphosphate via the enzyme, glycogen synthase. 
Jtta*. Has aifeimawas ss fcom "Buriogv: COHERES am! 
E. SimoE & L Dickey, 2009, San Franasca, Person Ei 
{d* eSf, by V. CaqibeQ, J. S J E B , M. Tayfar, 
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acetyl CoA + acetyl CoA 
ftoofon P * C o A 3-)^elnai-3-metfi)l ghaaiyl OaA mahtlase 
acetoacetyl CoA ' 
*Ttos reaction also | 
involves the 
of 
dmBckofidemdl 
^ 3-liydroxy-3-iitetlryl ghitaryl CoA 
beta hydroxybutaiate 
«*Tte5raacMaalso | 
im-otas te omdaofflu of ! 
*• acetoacetate 
i— succinyl CoA 
to Kreb's cycle 
| • — acetyl LoA 4 - | Srafce 
L— acetyl CoA - * J CoA 
Lp. <mcciaate 
acetoacetyl CoA 
Figure S Ketone Body Formation in the Liver and Breakdown in Skeletal Muscle The 
illustration depicts tbe OOEWTSKSII of 2 molecules of acetyl coenzyme A (CoA) mto the ketone 
bodies beta fayflroxybotarate, acetoacetate and acetone along with Ifae enzymes {m italics) that 
catalyse each reaction. Acetone travels through l ie bkod stream to the kidneys to be expelled 
walk beta byj&oxytaarate and acetoacetate enter the muscle cell to be broken down into acetyl 
CoA and enter the Kreb s cycle. 
&KL.SVSKSBS, 1962 BjodMrnical toimsaf, £4 211-216 sad 'Aspeos of KetogaMsss OHSrolsBsi Mechanism of 
E«oa^BodyFcEH!atKmmIssiteedIte-ljwr&famaM!Mtea' try Ml Lopes-Caradaso, I Mulder P Hermans S ran 
dm Ea^ i , W KlazBga, E de Vnes-Akkerman. 0 aL I97S Mofecalar mS. Cslteta Boactemaij 9,155-173, and 
iofExBinsei»hynology(3*1Ed),,,byW Metafile F Kateh&V Kaidi. 2086, Baltemsre, MD, 
cottWIaums&WiBaiB 
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njtnc oxide • - • guanyl cycia.se 
1 * 
^uanosmfi triphosphate cyclic gaanosme monophosphate 
1 
inhibits calcium entry mto the smooth muscle cell 
I 
inhibits vasoconstriction (attachment of myosin to actin) 
4 
* ^ 
Figure 9 Vasodilation Caused by the Effect of Nitoc Oxide in a Smooth Muscle Cell Kitnc 
oxide enters the smooth muscle cell and activates guanyl cyclase which conceits guanosme 
triphosphate into cyclic guanojme monophosphate Cychc goanosine monophosphate inhibits 
cakiam entry into the smooth moscle cell which mhiints vasocontraction by preventing myosm 
attachment to sens thus causing vasodilanoa. 
Note ItaiaisimawmBiraai'BiEfosePbysiijiogj Tta3iyami,A|sp]icatKMto 
Powers & E Bowtey, 2089 KEK Yadt, NY, McGraw-»ffi * 
M& 
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^ayldKsbms or tadykma or 
: stress of blood Sow DKNK1 vessel J 
& S ? J * 3 W K y S ^ 
I 
' endothelial c d h 
intracellular space 
increase in calcium 
* 
| 4 reacts wrth 
nitric oxide synthase {inactive) nitric oxide synthase (active) *• oxygen 
tetrahydrobiopterin 
L-citraHlme -*—| ' annates jEwactamof 
nitric oxide I L-arginine and nicotinamide adenine dinucleotide 
, endothelial cell 
to smooth muscle eel 
Figure 10. Formation of Nitric Oxide in wx Endothelial Cel. Acetylcholine, bradykinin or the 
shearing stress of blood flow act on a receptor located on the endothelial cell membrane and this 
caases in an increase i s calcium intracelMariy. The calcium activates nitric oxide synthase 
wMch reacts with oxygen and this caases the activation of tetrahydrobiopierim which initiates the 
interaction of L-araJEine and nicotinamide adenine dimicleotide. The interaction initiated by 
tetrahydrobiopteriii produces L-citniillme and nitric oxide. Nitric aside then travels to the 
smooth muscle cei to promote vasodilation. 
Norn. Ibis utfatmaSMSEis from "SUsrariBg Yasosta Kane Omde tNamadcrabr L^rgamgeliBpniVBi the SyngJHEts 
of ISKrnifttem OsmfealiDQ in PansEB with Periptignil Arterial Ckcksise Disease", by X. BOSH:, SJEode-Bogs, W. 
Tbdafe. A. Creatag, K. Aiexmsiieir & L Frohcfa, 1998, Journal of the Amancaa Coltoege of Cardsolegy, 32.133 6-
1334: ami "b Tvpe 2 Diabetes MelMns a Vascular Disease (Afteresclerapa&y} rah Hjpersiraraia a La* 
MsEffissaaii? The Rote of NCS, NO and Sfidox Stress", by M. HsydHL & S. Tyagi 2002,< 
v.2. 
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dyslipidmua and/or hyperglwemia 
I 
increased protein srgumne N-methvl transferase 
1 
assymetrical dimetfiylarginine 
: and nicotinamife adenine dinuclestide 
• does sot occur I 
oxygen 
peroxyBitrite < nitric oxide •*< .^. imces mfe. I 
""'^j superoxide 
transition metal * *" 'resets wift 
FigHW 11. Formation of Reactive Oxygen Species instead of Nitric Oxide in tie Presence of 
Dyslipidei3iia>''HypergryceniM. Dystipidemia and'or hypoglycemia cause the activity of protein 
srgmine N-metnyl transferase to increase and produce assymetrical dnaethylarginine, a L-
arginine inhibitor. Decreased L-argiiaine coacentraiios leads to nicotinamide adenine 
dmixleotide reacting oxygen (instead of L-arginiiie} and producing a superoxide. TMs 
superoxide can react wMh a transition metal or nitric oxide {formed in another cell or pathway) to 
form the superoxides hydroxy! or peroxynitiite respectively. 
Nam. Tfc lntmratiaD. is fiora -losuto-SeastsiBDe. ADMA Levete ami Cudunratrilar Disease", fry » . Nash. 2002, 
Journal of fla> .Ameocaa Medical AssodMioo, 2S7,1451-1452; n d "Nitric Oxide, Sqienmfe and Perasnmtnte: 
TbB Good, fee Bai m i the Ugly", fry J. Bedsman & W. Koprpead, 199ff. AaKiicaa Journal of Pbysiofo^-, 271, 
1424-1437; smd "Mtecksiadrial FarmaMMi of teems Oxygen. Specks", fry I.Tumms, 2003, Use Journal of 
Physiology, 552,335-344. 
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SR-A CDJ 
•" • < 
macrophage 
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Figum 12 Foam Cell Framation from Low-Density Lipoproteins in an Fjidofhelial Cell. Low-
density lipoprotein (LDL) enters the endothelial cell lad reacts with reactive oxygen species and 
the enzymes sphmgomyeimase, smetciy piKHphohpase and myeloperoxidase to foim oxidized 
LDL. The oxidized LDL is taken op by a macrophage through &e scavenger receptors SR-A 
and CD3 to create a foam cell that migrates to the endothelial cell membrane 
Mom Has iafijumattm us fesm. "AMmmmmiity. Blasting die A&eroscferock Plaqae'; byK. Rase & M. A&asiswra, 
2903, Harare MesJkme, 9,641 -642; and -THnstamg Molecular Btscovmes imp New Tberapies for 
Aflsmraderosfe'*. bvD. Ra te & A. Dan^ieny. 2JOTB, Nature. 451. 904-91 J. 
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glucose » ! giycojysu "j I" dihydroxyacetone phosphate 
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' •Ttereacnoaalso | «>1 coenzyme A — 1 1 ^cena-3-pkasphatBocyi tmn^sss 
EBP3>lT?£S She I d* A-
i-*rylgryceral-3 -phosphate 
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diacylglycerol 
Figure 13 Conversion of Dihytiroxy&cetoite Phosphate mto DiacylglceroL Gluocse enters the 
cell sad through the process of glycolysis is converted mto dihydroxyacetoae phosphate 
Dihydroxyacetone phosphate undergoes reactions catalyzed by 012511165 (m itahcs) to prodace 
dracyigloeFoL Some of these reactions mvolhre the addition of an acyi group that has been 
removed t u n coenzyme A 
Note The mfiramajm is fern "Proteus Kinase C Actraoim sissi 6m DepskipmeHi of Btabetic CampbcBBDHs", bj D 
Koya & G King. 199S, Diabetes 4" 6, g59-E8S sad '•Tkreuhpenient of Use YneSYgiH SMJ PlsX Protems 111 
Ptaptahpid Biasramescs m Bosk Baalhis SsiboHB and EsdierKhs Coif by M. Yostarara, T Oslraaa & K 
28S~ BMC Microbiology, 7, 69. and "Basrase Fhysfltogr TSSOIT aad Applicaaim to 1 
by 5 Powers &E Howie) 2009 Nen Ycsk NY, Mtfkaw-Hfli 
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increased diacylglwerol 
r protein kinase C (Hacn-ra) protein i kinase C (acto-e) • 
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bradinc of calcium to calmodulin 
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Figure 14. Protein Kinase C and Smooth Muscle Coatractien. Increased diacylglycerol 
concentration causes increased activation of protein kinase C which increases the calcium 
responsiveness in smooth musck contraction. As cafcram banfe to calmodulin, it activates 
myosin Jight chain kinase which subsequently activates the myosin light chain. This allows 
myosin to attach to actin and pal adjacent actin .filaments closer to each other. This occurs at 
many locations m the smooth muscle cell causing if to coHtracL 
Norn. HMS m&imatMm is fiom -•PrniMn Kinase C Artrraoca 
D. Kuya & G. King. 1998, Diabetes, 47,6, 859-BW; s 
2095. Hobofeea, IL, Mm Wiley & SODS. Inc. 
ami Ae Development of DrabMk: QrapJicMijojis", toy 
Amman? (10* e£f, by G. Tortura, 
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tyrosine kinase (mactive) tyrosine kmase (active) 
iatiacellmlar space 
insulin receptor substrate proteins (inactive) insHlin receptor substrate proteins (active) 
growth factor receptor bemud piotent 2 ^ _ „ t ™ * t o Src homology 2 protein 
Insulin receptor substrate proteins-Src homology 2 protein 
j unsafe receptor picteixis + 
j Src fctraoloay 2 protein + 
^owth factor xeeepEDx bound protein 2 
C ^ P T GDP I 
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Figure IS. Smooth Muscle Cell Proliferation Caused hy Hyperinsulinemaa., Insulin biacb is the insulin 
leeeptor and activates tyrosine protein kinase which activates msulm receptor substrate proteins wMch 
form a complex by binding to Sic homology 2 protein., growth factor receptor botmd protein 2 asd son rf 
sevenless. The complex activates Has fey removing euanosine dipio^iEate (GDP) and adding guasHjsine 
triphosphate! (GTP) Has activates Raf 2nd mitogsa-jictivated protein linase (MAPK) kinase is 
subsequently activated to initiate smooth msscie cell proliferation thorough MAPK. 
Note. Use infiHQHtKM is from "IssulJB-Iadaced. Mirogeit-Aaivatei Prosem (MAP) Kkiase Ptespaotoe-1 (MKP-1) 
Attemnies Iansim-SfiamlMed MAP Kmase Activity.. A Mechanism fin Fessfads Iohtbraaa. of Insulin Signaling". 
by A Kasan. J. Bvaa, D- BaaaVopMibMv, K. Kamaa; & J. Ensari, 1997, Molecoiar EadsKractogy, 11,10, 1532-
1543 
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triphosphate ^ adenosine dipfaosphsse + pkospfaate ion 
(ATP) eurci» (ADP) (P) 
* * 
ADP + creatme phosphate • ATP + creatine ADP - ADP 
Figure 16 ATP Production m the Pho-sphagen Energy System, Adenosine tnphosphate (ATP) is 
broken down during exercise into adenosine diphosphate (ADP) and a phosphate ictn (P) The 
ADP cm read with creatine phosphate (with the aid of the enzvme creatine kinase) to prodace 
ATP and creatine The ADP can slso react with mother ADP molecule (with the aid of the 
enzyme myokinase) to produce ATP and AMP (adenosine monophosphate) 
Now Has uafonEHtHm is from 'Eserase Physiology Ttasre m i Application to Frtaess and Pw&mmaLeT in. S 
Powas&E HowteT 20O9, New Tori KY McGraw-Hill 
113 
ATP/AMP ATP/AMP • ATP-»AI5P + P-»AMP-P-S» 
AT¥-»AMP-PPl 
ABP + ADP •* ATP- AMP 
I » 
AMP profeia kinase {usaajia^  AMP protein kinase (active) 
gtacose 
proton 4 
(GLUT4) 
gtacose 
tTaOSpCttT 
protein* 
(GLUT4) 
A 
S 
1 
6 
0 
-\ 
disssoatam from GLUT4 
• UUJX4 traissiocaiiOE so cell m 
4-i 
A 
S 
1 
6 
0 
intracellular space 
— cdii 
extracellular space 
Figure 17. GLUT4 Translocation caused by AMP Protein Kinase. Use ATP (adenosine 
triphosphate)/ AMP (adenosine monophosphate) ratio decreases wilt exercise due to the use and 
breakdown of the fuel ATP into ADP (adenosine diphosphate), AMP, PPi (pyrophosphate) and P 
(phosphate). AMP can also increase when ADP molecules accumulate (doe &J ATP breakdown) 
w& react with each after to form ATP and AMP. The increase in AMP activates AMP proiem 
kinase which is responsible from dissociating the inhibitory protein, AS 160, from the ^ucose 
transporter (GLLT4) allowing it to translocate to the cell membrane. 
i is from "SAMP-Atfiwed PtoteiB Kinase Aetraatkm caases GLUT4 TKmsiecaftoa in 
Skeletal Masde", try E. Krarh-Kxaczek. M, ffirshuME.. L Goodyear, & W. Windds, 1999, Diabetes, 4S, S, IM7-
lff71; amr-Gtasss Tinasfrart and Sisose Transports mMffid^ 
M. P&spet im>, Diabetes Cara, 13, 3,2SS-2S3. and "Modds IbcRegiilatkDa'by AMPSSKFlef Gtacoss Uptake m 
Muscle mil Gene Espresaaa m Yessf, by G. Birdie, 20Q2, Nature REVIEW Mateodsr Cell Biology, 8, 774-7B5. 
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sympathetic nervous system and/or Horepmephrin extracellular space 
i^yyJyyyyyMi ,
 c e l W a r m e m b r a n e 
^ ^ ^ ^ ^ intracellular space 
adenyi cyclase (mactive) adenyi cyclase (active) 
adenosine triphosphate cyclic ideBJsme monophosphate (cAMP) 
I * 
cAMP dependent kinase (inactive) cAMP dependedem kinase (»aira) 
Biacylglycerol J [^ adm^siae d t^aspfaare 
I 4 hormone sensitive lipase 
diacylglycerol + free fitly acid 
I diacylgbteral hpaza 
nionoacylgiycerol - free fetty acid 
I msxsmylglyceraLlipase 
glycerol + free fatty acid 
figure 18. Lipolysis: The Breakdown of Triacylglycerol into Glycerol and 3 Fatty Acids. The 
sjinpatteic nervous system and'or norepiEephiia act on a celblar membrane receptor causing 
the activation of adenyi cyclase and thus producing cyclic adenosine monophosphate and 
actn-ating cyclic adenosine monophosphate dependent kinase. Hormone sensitive lipase is 
phosphmylated and subsequently activated by cyclic adenosine monophosphate dependent 
kinase, and acts on toac3rlglyceroi to break it down to diacylglycerol and & free fetty acid. The 
enzyme (in italics) diacykglyoerol lipase breaks diaeyiglyceroi into a free fatty acid and 
menoacylglycerol which is broken down into glycerol and a free fetty acid. 
Nme.Thzs m&MBmtism a, fe«m ^ Exercise H^sWogv. Theory and Application to Fitness ami PmSozmamx", by S. 
POOTSS & E. Howley, 2009, New Task, NY, McGraw-Hill: "Principles of Human AaarsEny (10a tSf, by G. 
Xenons, 2905, Hobofaga. JL, Mm Wiley & Sons. Int.; "Essentials of Entose Paysrataey Q"1 Ed)", by W, 
McArdte, F. Each & V. Katck 200*5. Baltimore, MD, Ljfpncoa Wiiikms & Wiltons. 
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bile liver 
hormones "*"•'" steroidogenic cells 
[ HDL J 
* huh-density lipoprotein 
(HDL) ^thm 
acyl 
iLCAT) 
extracellular space 
cell] 
t t 
phospholipids cholesterol 
intracellular space 
Figure 19 Creation and Lifespan of High-Density Lipoproteins High-density lipoproteins 
{HDL) are created when alipaprotein Al combines with phospholipids and cholesterol 
(trsnsparted out of hepatic or mteftmal cells by the adenosine faphosphate-binding cassette 
transporter). HDL is acted on by the enzyme (in italics) lecithm cholesterol acyl transferase 
(LCAT) to create globular HDL which travels tfaroagh She blood stream collecting cholesterol 
from LDL (tow-density lipoproteins) and Mood vessel walls with lie aid of LCAT The 
globular HDL then travels to the liver or steroidogenic cells to father be excreted as bile or 
convened into hormones, respectively 
Katun RKIEWS Material CeE Biology. 9. 
Trafficking aii!l< byfi. 2008, 
12S-13S 
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Appendix A. University of Windsor Review Ethics Board Consent 
o 
lodav ' sJMe lone 24 2010 
Pntuipal investigator Martina kovacevse 
Rl B Number 2«^?6 
Research Project i ttl*_ Rl B» 10-101 I ovvct exfiemitv isometric training and its effects on t>pc 
2 diabetic claudication 
( Icanin t t Dale June 11 2010 
Project r nd Date \ u g i m 01 2011 
Milestones 
Renewal Duc-2011 08 OKPcndmgl 
1 his is to inform "sou that the 1 mversitv of W mdsot Research I chics Board (Rl B) which is organized 
and operated dccoidinsi to the 1 ti I ouncil Folic v Statement and tht 1 mversitv of \\ sndsor Guidelines tor 
Rese nch lnvolv m,a i iiiman Subiccts has granted approval to vour research protect on the d itt noted 
thinv I his approval is valid ottlv until the Piofeet i ml Date 
\ Progress Report oi I iiwl Report is due bv the date noted at>o\t I he Rt B mav ask tor monitoring 
information at some time during the ptojectaf^s approval period 
I Jut IIK* the course of the research no deviations from or changes to the piotoeol or consent form max be 
initiated without pnoi written approval from the Rl B Minor ehamiUs) m ongoing studies will be 
voiis'dered when siibmitud on the Request to Revise form 
Investigates must also report prompt I v to the Rl B 
at change' increasing the risk to the participant* s) and or affevisng significant!v die conduct of the siudv 
b) all adverse and unexpected experiences of events that are both serious and unexpected 
e 1 new mlormalion that mav adverxch affect the safet> of the subjects or the conduct of the smdv 
I ornis for submissions notifications or changes ate available on the Rl B website 
www itvurtdsor.c.{ rcb !1 vour data is going to be used for another pt oject it is necessarv to submit 
another application to the Rl R We wish vou cverv success m voui research 
"J 
Pierre tkuiios Ph f> 
% hair Research I tbics Board 
Ihis is an otftctal document Please tttam the orwinai m vour files 
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Appendix B. Windsor Regional Hospital Research Ethics Board Consent 
>H*- WINDSOR REGIONAL HOSPITAL 
*"* -
=> OUTSTANDING CARE-NO EXCEPTIONS! 
Research Ethics Board 
Delegated Review 
Review Date: October 14, 2010 
Project Title: Lower extremity isometric training and its effect on Type 2 
Diabetic Claudication 
Principal Investigator: Martina Kovacevic, University of Windsor 
REB File Reference: 10-201-21 
Items Reviewed: 
Ethics Submission Form dated October 6, 2010 
Appendix C - Poster and Flyer 
University of Windsor Ethics Approval Letter dated September 22, 2010. 
Letter to Research Ethics Board - undated (received October 6, 2010. 
Solicitation for participants for your research from Windsor Regional Hospital's Patients in the 
Cardiac Wellness Program. 
Approval has been granted for placement of Research Participant Recruitment Poster. Flyers 
may be left in waiting area for any patient who chooses to take one. Eligible patients are not 
to be identified by being distributed flyers as this would constitute a breach in patient privacy 
and confidentiality. 
This Research Ethics Board is constituted and operated in accordance with the Tri-Council Policy 
Statement for Ethical Conduct of Research Involving Humans (TCPS), Canadian Food & Drug 
Regulations, Division 5 (Clinical Trials), ICH Good Clinical Practice Guidelines E6, Personal Health 
Information Protection Act, 2004 (PHIPA), U.S. Code of Federal Regulations Title 21 & 45. 
Only Research Ethics Board members who are independent of the investigator(s) conducting the 
study participated in decisions relating to this research. 
COPY 
Wallace Liang, MD., LLB., MHsc. 
Chair, Research Ethics Board 
Windsor Regional Hospital 
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Appendix C. Poster Advertisement 
oi Wmds. 
Leg Pain /Cramping and Type 2 Diabetes Study 
Be part of an important leg pain and cramping study; 
• Are you over the age of 18 ? 
• Do you have type 2 diabetes? 
• Have you been diagnosed with peripheral arterial disease9 
• Do you feel pain or crampmg in your legs after walking short distances? 
If you answered YES, you may be eligible to participate in a research study 
Please contact Martina Kovacevic at (519) 253-3000 ext 4979 
kovacevm@uwindsor.ca 
•study cleared by tte Umvaraly of Wm&nr HeiKris BMrs Board 
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Appendix D. Letter of Information for Consent to Participate in Research 
(J University 
of Windsc" 
LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN RESEARCH 
Title of Study: Lower extremity isometric training and its effect on type 2 diabetic claudication 
You are asked to participate in a research study conducted by Martina Kovacevic and Dr. Cheri 
McGowan from the Department of Kinesiology at the University of Windsor as a requirement of Martina's 
master's level thesis. 
If you have any questions or concerns about the research, please feel to contact Martina Kovacevic at 519-
253-3000 ext 4979; or Dr. Cheri McGowan at 519-253-3000 ext 2451. For questions or concerns during 
non-working hours, please contact Dr. Cheri McGowan at 734-904-8488. 
PURPOSE OF THE STUDY 
The purposes of this study are to determine if isometric leg (i.e., squeezing your calf muscles without moving 
them) training will improve lower leg blood flow, delay the progression of peripheral arterial disease and 
reduce the leg cramping that happens with walking in people with type 2 diabetes. 
PROCEDURES 
If you volunteer to participate in this study, you will be asked to: 
INITIAL VISITS: 
After expressing interest in this study, you will be asked to come to the Physical Activity and Cardiovascular 
Research (PACR) Lab (Room #240, Kinesiology Building, University of Windsor, ON, Canada) to sign the 
necessary forms, fill out a medical questionnaire and receive the physical activity readiness medical 
examination to be filled out and signed by your doctor. At this time, you will also arrange a date to visit the 
PACR Lab again to familiarize yourself with the equipment and lab, and find out whether you are in the 
training (exercise) or non-training control (blood pressure monitoring) group. 
TESTING DAY (approx. 1 hour): 
You will be asked not to drink or eat alcohol or caffeine for 12 hours before the visit and not to smoke for 30 
minutes before the visit. You will need to come to the PACR Lab dressed in a short-sleeved shirt, shorts 
and comfortable walking shoes. You will be asked to rest for ten minutes, then blood pressure 
measurements will be taken twice in each arm and four times in each leg. Following this, ultrasound 
pictures of the popliteal arteries (large arteries in the back of the knee) will be taken on both legs using a 
wand-like instrument covered in gel. You will then be asked to walk on a treadmill at 2 mph with an 
increasing incline for as long as you feel comfortable. Ultrasounds pictures of your popliteal arteries will be 
taken again once you complete the walk. 
This testing day will be repeated at the end of the 8 week training period whether you are in the training or 
non-training group. 
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TRAINING DAYS FOR TRAINING GROUP (approx. 45 minutes): 
Approximately 1 week following the testing day, you will be asked to visit the PACR Lab 3 times per week for 
8 consecutive weeks for isometric leg training Prior to the training session a pre-exercise and post-exercise 
finger-prick test to measure blood glucose to make sure that it is not too low (if it is you will be offered a 
snack) The training will consist of performing exercises using a machine resembling a desk, where you sit in 
a chair at the desk and press up on the desk top from underneath with your knees by trying to point your 
toes The exercises will last for 2 minutes followed by a 2-minute rest period, and this will be done 4 times 
The training day will begin with 10 minutes of rest and blood pressure measurements in the arms and legs 
The exercises will be performed next and blood pressure measurements in one arm will be taken every 2 
minutes Following the exercise, blood pressure measurements will be taken in the arms and legs again 
TRAINING DAYS FOR CONTROL GROUP (approx. 30 minutes): 
Approximately 1 week following the testing day, you will be asked to visit the PACR Lab 3 times per week for 
8 consecutive weeks for blood pressure monitoring You will need to be dressed in a short-sleeved or 
sleeve-less shirt and after resting for ten minutes, blood pressure measurements will be taken twice in each 
arm and four times in each leg 
POTENTIAL RISKS AND DISCOMFORTS 
You may experience tendonitis in the tendons of the legs with isometric training, however, this risk is 
minimal if the exercise is properly performed The blood pressure and blood flow measurement procedures 
are non-invasive, but you may experience numbness or tingling with the cuffs while we are taking our 
measurements You may also experience some tenderness in the areas of the finger-prick test 
The intermittent claudication test (treadmill walking) is a safe test when used properly, and when participants 
have been appropriately screened (which you will be once you have filled out the medical questionnaire and 
your physician has completed physical activity readiness medical examination) Occasionally, for safety 
reasons, we may have to stop the test In cases of emergency, you will be given first line treatment, as 
appropriate Our laboratory's emergency action plan (EAP) is posted in the laboratory 
Please contact one of the study investigators if you feel any adverse effects from completing any portion of 
the study, and/or if you have any questions or concerns Study investigators will reinforce proper training 
technique throughout the study If you experience any adverse effects during any testing procedure, first 
line response will be provided 
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
You will benefit from this study by having your blood pressure measured, recorded and tracked for a ten 
week period You will be given this data upon request for your medical history This study will also provide 
you with new and different exercises to help control symptoms of claudication 
The scientific community and society will be able to use this study for information on non-drug-related ways 
to control peripheral arterial disease and blood pressure because medications are usually expensive and 
give the user unwanted side effects 
COMPENSATION FOR PARTICIPATION 
You will receive a University of Windsor Kinesiology Research t-shirt You will also be reimbursed for 
parking fees and the potential fee for completion of the physical activity readiness medical examination and 
medical release by their primary care physician If you were assigned to the non-training control group will 
be given the chance to take part in the training exercises after the study is done 
122 
CONFIDENTIALITY 
Any information that is obtained in connection with this study and that can be identified with you will remain 
confidential and will be disclosed only with your permission 
You will be assigned an identification number. Your name will not be used in any information 
collection, publication or presentation. 
All paper and electronic data will be stored in a locked laboratory of the principal investigator Information 
stored on computer will be password-accessible only, and will be available only to the study investigators 
Upon publication of the study, all paper records will be shredded 
PARTICIPATION AND WITHDRAWAL 
You can choose whether to be in this study or not If you volunteer to be in this study, you may withdraw at 
any time without consequences of any kind You may also refuse to answer any questions you don't want to 
answer and still remain in the study The investigator may withdraw you from this research if circumstances 
arise which warrant doing so 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS 
Research findings will be available to participants by mail or email. Results will also be posted on 
the University of Windsor's Research Ethics Board (REB) website in August 2011. 
Web address 
Date when results are available 
SUBSEQUENT USE OF DATA 
This data will not be used in subsequent studies 
RIGHTS OF RESEARCH SUBJECTS 
You may withdraw your consent at any time and discontinue participation without penalty If you have 
questions regarding your rights as a research subject, contact Research Ethics Coordinator, University of 
Windsor, Windsor, Ontario N9B 3P4, Telephone 519-253-3000, ext 3948, e-mail ethics® uwindsorca 
SIGNATURE OF INVESTIGATOR 
These are the terms under which I will conduct research 
Signature of Investigator Date 
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Appendix E. Consent to Participate in Research 
University 
of Windsor 
CONSENT TO PARTICIPATE IN RESEARCH 
Title of Study: Lower extremity isometric training and its effect on type 2 diabetic claudication 
You are asked to participate in a research study conducted by Martina Kovacevic and Dr. Cheri 
McGowan from the Department of Kinesiology at the University of Windsor as a requirement of Martina's 
master's level thesis. 
If you have any questions or concerns about the research, please feel to contact Martina Kovacevic at 519-
253-3000 ext 4979; or Dr. Cheri McGowan at 519-253-3000 ext 2451. For questions or concerns during 
non-working hours, please contact Dr. Cheri McGowan at 734-904-8488. 
PURPOSE OF THE STUDY 
The purposes of this study are to determine if isometric leg (i.e., squeezing your calf muscles without moving 
them) training will improve lower leg blood flow, delay the progression of peripheral arterial disease and 
reduce the leg cramping that happens with walking in people with type 2 diabetes. 
PROCEDURES 
If you volunteer to participate in this study, you will be asked to: 
INITIAL VISITS: 
After expressing interest in this study, you will be asked to come to the Physical Activity and Cardiovascular 
Research (PACR) Lab (Room #240, Kinesiology Building, University of Windsor, ON, Canada) to sign the 
necessary forms, fill out a medical questionnaire and receive the physical activity readiness medical 
examination to be filled out and signed by your doctor. At this time, you will also arrange a date to visit the 
PACR Lab again to familiarize yourself with the equipment and lab, and find out whether you are in the 
training (exercise) or non-training control (blood pressure monitoring) group. 
TESTING DAY (approx. 1 hour): 
You will be asked not to drink or eat alcohol or caffeine for 12 hours before the visit and not to smoke for 30 
minutes before the visit. You will need to come to the PACR Lab dressed in a short-sleeved shirt, shorts 
and comfortable walking shoes. You will be asked to rest for ten minutes, then blood pressure 
measurements will be taken twice in each arm and four times in each leg. Following this, ultrasound 
pictures of the popliteal arteries (large arteries in the back of the knee) will be taken on both legs using a 
wand-like instrument covered in gel. You will then be asked to walk on a treadmill at 2 mph with an 
increasing incline for as long as you feel comfortable. Ultrasounds pictures of your popliteal arteries will be 
taken again once you complete the walk. 
This testing day will be repeated at the end of the 8 week training period whether you are in the training or 
non-training group. 
TRAINING DAYS FOR TRAINING GROUP (approx. 45 minutes): 
Approximately 1 week following the testing day, you will be asked to visit the PACR Lab 3 times per week for 
8 consecutive weeks for isometric leg training. Prior to the training session a pre-exercise and post-exercise 
finger-prick test to measure blood glucose to make sure that it is not too low (if it is you will be offered a 
snack). The training will consist of performing exercises using a machine resembling a desk, where you sit in 
a chair at the desk and press up on the desk top from underneath with your knees by trying to point your 
toes. The exercises will last for 2 minutes followed by a 2-minute rest period, and this will be done 4 times. 
The training day will begin with 10 minutes of rest and blood pressure measurements in the arms and legs. 
The exercises will be performed next and blood pressure measurements in one arm will be taken every 2 
minutes. Following the exercise, blood pressure measurements will be taken in the arms and legs again. 
( / 
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TRAINING DAYS FOR CONTROL GROUP (approx. 30 minutes): 
Approximately 1 week following the testing day, you will be asked to visit the PACR Lab 3 times per week for 
8 consecutive weeks for blood pressure monitoring You will need to be dressed in a short-sleeved or 
sleeve-less shirt and after resting for ten minutes, blood pressure measurements will be taken twice in each 
arm and four times in each leg 
POTENTIAL RISKS AND DISCOMFORTS 
You may experience tendonitis in the tendons of the legs with isometric training, however, this risk is 
minimal if the exercise is properly performed The blood pressure and blood flow measurement procedures 
are non-invasive, but you may experience numbness or tingling with the cuffs while we are taking our 
measurements You may also experience some tenderness in the areas of the finger-prick test 
The intermittent claudication test (treadmill walking) is a safe test when used properly, and when participants 
have been appropriately screened (which you will be once you have filled out the medical questionnaire and 
your physician has completed physical activity readiness medical examination) Occasionally, for safety 
reasons, we may have to stop the test In cases of emergency, you will be given first line treatment, as 
appropriate Our laboratory's emergency action plan (EAP) is posted in the laboratory 
Please contact one of the study investigators if you feel any adverse effects from completing any portion of 
the study, and/or if you have any questions or concerns Study investigators will reinforce proper training 
technique throughout the study If you experience any adverse effects during any testing procedure, first 
line response will be provided 
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
You will benefit from this study by having your blood pressure measured, recorded and tracked for a ten 
week period You will be given this data upon request for your medical history This study will also provide 
you with new and different exercises to help control symptoms of claudication 
The scientific community and society will be able to use this study for information on non-drug-related ways 
to control peripheral arterial disease and blood pressure because medications are usually expensive and 
give the user unwanted side effects 
COMPENSATION FOR PARTICIPATION 
You will receive a University of Windsor Kinesiology Research t-shirt You will also be reimbursed for 
parking fees and the potential fee for completion of the physical activity readiness medical examination and 
medical release by their primary care physician If you were assigned to the non-training control group will 
be given the chance to take part in the training exercises after the study is done 
CONFIDENTIALITY 
Any information that is obtained in connection with this study and that can be identified with you will remain 
confidential and will be disclosed only with your permission 
You will be assigned an identification number. Your name will not be used in any information 
collection, publication or presentation. 
All paper and electronic data will be stored in a locked laboratory of the principal investigator Information 
stored on computer will be password-accessible only, and will be available only to the study investigators 
Upon publication of the study, all paper records will be shredded 
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PARTICIPATION AND WITHDRAWAL 
You can choose whether to be in this study or not If you volunteer to be in this study, you may withdraw at 
any time without consequences of any kind. You may also refuse to answer any questions you don't want to 
answer ana still remain in the study. The investigator may withdraw you from this research if circumstances 
arise which warrant doing so. 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS 
Research findings will be available to participants by mail or email. Results will also be posted on 
the University of Windsor's Research Ethics Board (REB) website in August 2011. 
Web address: 
Date when results are available: 
SUBSEQUENT USE OF DATA 
This data will not be used in subsequent studies 
RIGHTS OF RESEARCH SUBJECTS 
You may withdraw your consent at any time and discontinue participation without penalty. If you have 
questions regarding your rights as a research subject, contact. Research Ethics Coordinator, University of 
Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 3948; e-mail: ethics ©uwmdsor.ca 
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE 
I understand the information provided for the study Lower extremity isometric training and its effect on 
type 2 diabetic claudication as described herein. My questions have been answered to my satisfaction, 
and I agree to participate in this study. I have been given a copy of this form. 
Name of Subject 
Signature of Subject Date 
SIGNATURE OF INVESTIGATOR 
These are the terms under which I will conduct research. 
Signature of Investigator Date 
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Appendix F . Medical Questionnaire 
Medical Qiiestiomiaire 
LastXms FsntKm* 
Aatas Cm 
Pnrcire* 
Height W«gu Ses, 
DsterfBirth HoaiaPtooe? { ) PosfilCofe 
fcfa* Y « 
FOR EMEXC-EXCY NOTIFY: 
Address mcme(_ 
Family Doctor's Nuae Cwe oflast BressoU 
Please Check Yes or No: YES 
1. Hraysuliemfogiiosediiifttypelc 
2. Hnaf«tl!«» i!ia^yise£ or «e nods'«eia>[iic»c of psraterd aittdal c 
3. Biwymwmha&swwrf* 
If yes, please speniy? 
4. Are jDcpiesa^ldiiiigmvaiHiicitioiEarp* (iELWiag«5pirmaad8 
Kyes.F^speriSr? 
5. Do JOB. Ian aw silkrms (lE^kin*. tod, bses or o«faax sangiiig insectey 
If yes, please sperif}-? 
6. Esraymierar fell dizzy or passed ew&raigsK after essase" " 
7. EarayD-aeirahMd^faistoiag^sfiarexeidse7 
*. DoTDulralEgjilft^pnsiaicagipcrie^^ 
9. H^ f iwawbeml i r fd lMyj i a l ^a l i i ^ i r t lH^ 
16 D® yrai te* aay drin pratera (Ltdaug, nsbes. acne)? 
11. Ify^MIe^^IieE^!eal!ll>wtoaffiasde,}DyoE^Ili^e^saJ', 
12. DDfoabraAsftmiarmyMl 
'ifyEs.pkaseEjedfi" 
13. Do you tas soy type of c 
If yes, please sperily?^ 
14. DuyimsEEAe? 
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Appendix G. Physical Activity Readiness Medical Examination (PARmed-X) 
R^q ila ph/st -a! an tvst* is f u " an *< healthy ^rui r i ue is i rq / 1 H L n . i w l t eif start r g u P^u )rr e rrnj r * *!***-*/" v ddy B ^ n ^ mor" ACUJ~ 
ver, j j f s for Ttost p^ _§Je "Tic P4R C by IS e)f provide" j j e q u d t - " I M nq fry t r v f i s p t i t y <f f eor l t H »ev J r * f" tndi " r tu i ls rr iv 
f - iu i f a w d L.al •'valurf; to 1 arid H I ^ I ? <-ddu~~> 1 » r u f t *s i p l 1 ! i to utin i r m r c I X ^ I V P it * j r t j s he PAH J 
r o l ' o w n f e part p jnrt .»aval w i s 11 /v< i ihy3 t an a p " / j c i f a < n t iyplari s r^u ld be d a . i i e i i 1 „ a 13 j ttat pi » i r a physical dr tu i ty 
JI ips»crial
 ( _ S i : P - ' l o l . j i i . r i d l f 1 i ^ 5 I fctylfc Cm ult irrt t r f S F P Fxf» p T r m p s t ™ l i u ^ , 1 f tht Mluwinq it M r j t u i» 
3 t . f r )«d^>d 
PAGE 1 S r' lon A n ' ir t tt->>i i l d b s c m p l f * d o» We panr ipan B U OH. , the examii ia*it i o v l i f p / ic an Fne fcottcm 
se-t Ji* 10 to \y eornpsf t* d fo) he exart nil c piyaician 
PAGES 2 & 3 A r e c k l m c" t r e s e s ! rnra1i»nr« rf qmr "ig <*po-ni cs s 1 - r i t in and i r w i s o r f W 
PAGE 4 -s^ i y - i c i V i v ! \ £ L K ytu Ad^ic0 tc peo >!•» wh 5«. a t o r ^ i iri»i,p<*ri in«-fr h.t m s o " v c a o e r l e w t c i f 
^hy^i^a A c ' w i / Rccd in t^s €< nvey^n ^ H ^ r t a ! F rr a 1 c.£.U t n ! s-^MfM- i^ f tb f n* / i s ti t c nvey dea*an ~* f r 
&.rvM^t-& r ^ 1 / pats-, t.'-t's r't ot to t m k e a notarial o a r wo kally s j p n r v ^ ^ d % <** * * *,< u n i t 
:lOT)liii»c*Wi:1» M«^^^l lW'lhfc#irtt«; l i i»irt8 
PERSONAL INFORMATION" 
4 
rjiSfiP _ 
PAR Q P<-1 ' > « 
.vn r h vo t answered ^" 
-'A J ,„ 4! r 'Js n ! to 
- p i F 3 „ f)E-_ 
HR H ~TF 
U 1 Hea ^ ro i i t u n 
Q <t F he t p^tn trtr n t ^t ivt y 
(j 1 C h o J nam a can 
O 4 L C S r f o a t e n di^z rii»s 
O ^ S ^ e )i j n pr )M* m 
O u 8luoJ p t3 s j r ^ at r ectl drues 
O "' O hat easu 1 
C*K± 
R I S K F A C T O R S F O B C A R D I O V A S C U L A R D I S E A S E 
Cruc-. as t?>8 app t 
t *£•- star 10 rr ft «*><• o' medwa is ; 
xi livi ^ nt > l ty t t >*>eek 
ut rei 1 f v t n u l - ?r 11 jpaccn smok n t 1 ot 
Hit,! rjlaoo j ieSoUts epor*na 
by pnywf w i f « tepeatpd r iaosurerrents 
H i j h cfiotehtB t.1 lav»t repcrt^d py physinar 
Lk P » S v<? aceuriLlatirirs of fat arcane 
Fa^ i iy rissr.0 y of hr ^rr d r c i r r 
Please note A*a^ o ' ?'«»•«; •< « to Br^ 
aftddHCjt<i ¥**m$Qi*rpft'*r w 
P H Y S I C A L A C T I V I T Y 
I N T E N T I O N S 
What phys -ni act > isy dc you rtlend to do? 
Tivic section to b« compl«t*d by th« •xamlrtino physician 
Physical Exam 
Ht 
BP us 
Conditions iirmtmg physical activity 
j Muscutosl- elr ta 
T e s t s r e q u i r e d 
J FStaJd 
J Rasptatory 
J Abcomsnai 
j fc«e c i s f T e ^ 
j Urinalysis 
_i X Ray 
J Otho 
P h y s i c a l A c t i v i t y R e a d i n e s s C a n v e y a n c e / R e f e r r a 
[?8»od upon ..t c j r r c r t r ey i e * o* ftealth - ifnt- r 11 mm 
st i tus t ^^omr r^ rH 
. j Nu pi /sir s^l a< t ivtt/ 
J 
J A tdl*n* O 
wi 1 1 V J I e j 
_i Av 5 11 t >ES | i r s 
Drsly a rr dicalii, oppprwsod exorcist prog'am until I j f th f 
mecical c le- i rarfa 
j Progress ve p i iy^^a i a ftvity 
3 »i t l a . q J a ii,e of 
J t\lr » Uusicn j f 
j t i rder tr>*» b jp f fv is ion ot a CCJCF ProteS6ioi>ai F tnass. & 
U e^f j t leGor^uBarto C b L P Li.eta58 IheraDis * 
j Unrest' J e d physical ad vrty-stad slowly and bi,iid I p ]ractaa! V 
csfgpt 
Gsr^ id Canada 
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£ f J vd i t^r c 
Absolute Relative Special Prescriptive 
Contraindications Contramdicatfons Conditions 
1 X G ™ e-Tt # a » / IJ * r » H i J f, 
u -t SM a t § s,*ws>° ° ac3 k A 1 r i a 
t * a i ^ r 
J 
JL S { 1 a r "i v 
j t a > v 
J 1 t 4 b 
j v«- i fa 3 f v ca t, a i 
t « 
r t i i f 
1 st -J i\ f 
J I f 3 3 3 >r °H 
i 
i 
t "} s> c 
C r "£ A 
1 f-"S 
( a c - f iS j .&Ot '^ 13 } 
j T f a iv>* s * pa * * ^ ^ f 
j Jt *) n if* i 
i t t ! <> 
.J *>$ f i * j rtsnt J f- T i a a 
ADVICE 
£ f * -<><•* r U 
f i f i I f 3 1 
n t o rfi4 a 
f , 
•& n> «<; c f s 
* 3f •«. -si J M 
re r* r r a r a ^ >v* 
1 t u 
<> C 3 J 
l i f * < ! r n f 
Si i*< r t i i 
i f 7 3 -
p r t c ^ 
r 1 * r ^ 
hfle bo lk 
t- r 3*i^'k*y 
f Ja e a ^ ! t d f JS 
3 / V t l ^ ? » ! i 
i u r r 
j c t i t t i ^ ( J o t r> V a i 3r t P"hma1 > c 
A C L \ \? r * % <*i Toward Active Living 
Actiwff> Ftirssss. and Hsaith t } t~ >< 
P A . " "> v f - t i n t n P * t f « r t & t ! i t : M ry f i- I ' « 
> ht i f TAR it Can J Spt Sci n 
Th^ PAR J a i i f f Hf^Ld < wt r il^vt Jr'pwr oy ^ t Bf ssh os imh •> 
->1 ^f t»i M n st v cf HOJ!? I hf y ha A* b^e r " n x c oy ar b^pct Adv ^c » 
'
 fc !
^ o fp i i of of tl %, Cafkid a ^us.!g / lor I xar^ s«* P^yssoSoq/ J- ir^d 
No c h a n g e s p e r m i t t e d You a r e e n c o u r a g e d t o 
p h o t o c o p y t h e PARmed-X b u t o n l y sf y o u 
u s e t he ®ntim f o r m 
r H'X rs 5® en *farga « u^ 1 \?r 
€ e i j j 
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Special Prescriptive 
Conditions ADVICE 
trie Pn^cM AcI'vHy' &«>;sE!im»&K. Question's *|F(?! PAW ii f t i * " v > * !;-* c o > ^ > : « b^'f^>> »>• 
PI i t I A l l . I» R<«4in v V<<!lt i l ( « « ICI-wtlon rof S»r«9M«rt«» (PAfinitai-H tSU MieGNAI\ iCY) -tr . C:r; y ! i f N ! fcy j 
Note to physical activity professionals... esstdjk 
II is a KsuA-'nt p rac t ice to isWi i f »K> COmpiflseiS Pny;,.f,ai AcSMfy i j j SBM 
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? * *
r < x 
V 
l««<sas« $&&%m& IRCT«3S« 
arm jt&rfs *&&£ 3** 
Sfcrm$#) 
4 s*s «EJ&. 
tow -S «. «**»?<< W £f» Sl*» 
^ 
feSfv^ 
-s^-^-s? 
1*1 
PARmed-X Physical Activity Readiness Conveyance/Referral Form 
^ ^ d pen s c r $-ft r>« ft^y i,* h** i i r e tis*-
_i N phv«; at Kt v
 v 
_j O y 'i mrd iHj^ j> ^ ^ d >Pi f >qrm w t l furlht f m Us ! 
j Pmgt> ^ « phys i l i w r y 
Lf*~sty!e < ^ n ^ j i u i i o L * I XPr sse Thprat: fst ** 
^ Unr s\m& phv*-&3i i&l v?u - art o ^y ^ n r f ^Ui i f" *-& q r ^ u sJSy 
' a t i 
NOTE Thts physscal activity clearance i§ VSIH! 
lor P maximum of sss* months from the date 
st is completed and becomes invalid it your 
medical con4i\mrt fof*com©s worse 
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Appendix H. Personal Medical History Questionnaire 
Type 2 Diabetes 
1. When were you diagnosed with type 2 diabetes? 
2. What is your current method ol control for type 2 diabetes7 
3 How long have you been using the current method of control7 
4. What were your previous methods of control7 (description, dates) 
Peripheral Arterial Disease (PAD) 
1. When were you diagnosed with PAD? 
2. Are you currently taking medication to control PAD-related pain? 
If yes, how long have you been taking this medication? 
3. Are you performing any activities to help reduce PAD-related pain? 
If yes, please describe: 
Exercise 
1. Do you exercise regularly7 Y/ N 
If yes, what type of exercise do you perform and how often? _ 
If yes, how long have you been doing this exercise? 
2. Where you active in previous years? Y/N 
If yes, please describe the type of activity and its duration 
The Study 
1. Why did you join this study? 
2. What encouraged you to complete the study's exercise program? 
3. Did you find the exercise program helpful? 
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Appendix I. Release of Medical Information 
University C<F 
ofW.pdsci 
Department of Kinesiology rt«*ngtomoid 
RELEASE OF MEDICAL INFORMATION 
authorize 
to release any information regarding my medical condition to 
Martina Kovacevic, BHK 
Department of Kinesiology 
University of Windsor 
HK 240, 410 Sunset Avenue 
Windsor, ON N9B 3P4 
FAX: (519) 973 7056 
Signature: Date: 
Details of information being requested: 
health status with respect to blood pressure, type 2 diabetes, peripheral arterial disease 
and cardiovascular health during the past twelve (12) months 
o I, Martina Kovacevic, have explained the details of the Release of Medical 
Information Form to the participant 
Signature : 
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Appendix J. Automated Arterial Oscillometry Device 
; . . , . . . \ . * • • * -**•* •"" ' 
Dinamap ProCarelOO, Critikon 
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Appendix K. Duplex Ultrasound Machine 
tj': •'•••<•• 
tort-A"*.- > 
—«-a 
8s< 
• - i tf 
»J 
\ 
GE Vivid i 0334 Ultrasound Machine 
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Appendix L. Gardner Protocol 
Gardner Protocol 
The Gardner Protocol is a validated test (Gardner et al., 1991) used clinically to assess 
intermittent claudication with the use of a graded treadmill. 
The protocol is as follows: 
1. The individual begins to walk on the treadmill at 2 mph at 0% incline. 
2. While the individual walks at a constant 2 mph, the treadmill incline will increase 
by 2% every 2 minutes. 
3. The treadmill will continue to incline to a maximum of 14%. 
4. As the individual is walking, he/she will notify the investigator when pain and 
cramping are first felt in the legs (this is the initial claudication distance, ICD). 
The individual will continue to walk. 
5. Following the determination of the ICD, the individual will notify the investigator 
at the appearance of maximal pain and cramping (this is the absolute claudication 
distance, ACD). The individual will discontinue walking on the treadmill. The 
ACD may occur before the maximum 14% incline. 
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Appendix M. Blood Glucose Monitoring System 
^Srk 
ffe;k.'4if"J''.,|! 
tff?>*;.** JW1- i 
A" 1 
Abbott FreeStyle Freedom Lite 
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Appendix N. Spring-Loaded Lancet 
Accu-Chek Softclix 
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Appendix O. Lower Leg Isometric Training Apparatus (LoLITA) 
a 
Titf " i H S " 1 *•*<*** ^ W l * * 
Profile view of LoLITA Frontal view of LoLITA 
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